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Abstract 
 Paper-Based Point-of-Care Tools for Blood Testing 
 
Xuefei Gao 
 
Early detection of malignant disease is crucial for timely diagnosis and effective medical 
intervention, which significantly increases survival rates and reduce financial burden on patients. 
Biomarkers are becoming increasingly important in detection of malignant diseases, because 
they can be employed for indicating diseases, predicting risks and monitoring the progression of 
diseases. In addition, biomarkers show up at early stages of diseases in human tissues and fluids 
(e.g., blood, urine and saliva), which shows great promise for early disease detection. In this 
dissertation, paper-based lateral flow strips (PLFSs) have been developed for the detection of 
disease biomarkers, including protein biomarkers and microRNA (miRNA) biomarkers from 
clinical samples and whole blood samples. Among most of the reported biosensors, PLFSs 
appear to be an effective tool for providing access to point-of-care (POC) applications, due to 
low cost, fast response, portability and ease of use. In addition, paper is compatible with 
biological samples, which allows its application in analyzing various biomolecules. However, 
conventional PLFSs exhibit insufficient sensitivity and poor interference resistance. In particular 
whole blood samples, which contain numerous interference biomolecules, substantially affect 
detection accuracy and specificity. 
In this dissertation, several strategies have been employed to solve the problems, including 
introducing PLFSs with ultrasensitive techniques, meanwhile modifying PLFSs with functional 
nanomaterials and paper accessory unit to reduce the interference biomolecules from human 
fluids. In summary, five chapters will be demonstrated:  
(1) Surface-enhanced Raman scattering (SERS) technique modified PLFSs for protein 
biomarker detection in clinical blood plasma samples. In this chapter, silica coated SERS 
nanoparticles (NPs) have been developed for improving Raman signal and detection sensitivity, 
at the same time, silica coating of the SERS NPs substantially improve the stability of the NPs in 
complex human fluids. As a result, the developed SERS-PLFS can realize direct detection of 
neuron-specific enolase (NSE) from clinical blood plasma samples of traumatic brain injury 
(TBI) patients. The test results of the SERS-PLFSs were compatible with those from the standard 
enzyme-linked immunospecific assay (ELISA) method;  
(2) Blood plasma separation unit (PSU) integrated PLFS for cancer protein biomarker 
detection from whole human blood sample. In this chapter, a paper based PSU was fabricated to 
efficiently retain red blood cells (RBCs) inside the unit to block their migration and meanwhile 
push the target protein contained plasma to the detection area of the PLFS. As a result, cancer 
protein biomarker-carcinoembryonic antigen (CEA) was successfully detected by the PSU-PLFS 
from whole blood samples; 
(3) Plasmonic chip and PSU integrated PLFS for protein biomarker detection from whole 
blood. In order to meet the high sensitivity demand, a gold nanopyramid array functionalized 
chip was integrated into a PLFS for amplifying Raman signal and ultrasensitive detection of TBI 
protein biomarker s-100β; while the PSU was utilized to reduce the RBCs interference from 
 
 
whole blood. As a result, compared with the result of the SERS-PLFS in Chapter 2, an 
improvement in LOD with two-order of magnitude was obtained; 
(4) Near-infrared fluorophores (NIRFs) functionalized PLFS for miRNA detection from blood 
plasma. In this chapter, NIRFs encapsulated silica nanoparticles were synthesized and 
incorporated into a PLFS for stroke biomarker miRNA-34 detection. Compared with a single 
fluorescent dye, the synthesized NIRF NPs encapsulated numerous fluorophores into one single 
silica nanoparticle, exhibiting amplified luminescent intensity. Moreover, the NIRF nanoparticles 
minimized the fluorescent background from biological matrices and test strip materials, which 
elevates signal-to-noise ratio and anti-interference capacity; 
(5) Duplex specific nuclease (DSN) based signal amplification strategy modified PLFS for 
ultrasensitive miRNA detection in blood plasma. In order to meet the high sensitivity demand of 
miRNA-34 measurement from the clinical blood plasma of stroke patient, the developed NIRFs-
PLFS in Part 4 was further elevated with DSN modification for amplifying fluorescent signal. As 
a result, the DSN-PLFS exhibited an improvement in detection sensitivity with two-orders of 
magnitude in blood plasma.  
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Chapter 1: INTRODUCTION 
1.1 BACKGROUND AND MOTIVATION  
A critical and challenging future direction in science and engineering is to develop 
technologies to improve the health of people in the developing and remote regions of the world.1 
However, advanced diagnostic technologies are always centralized and requiring sophisticated 
instruments, specialized laboratory personnel and expensive chemicals. Moreover, continuous 
and long term monitoring add tremendous time and financial burden on patients due to 
soaring costs and frequent travel to hospitals and institutions. These factors have accelerated the 
emphasis on the development of low-cost, easy-to-operated and reliable devices to shift 
diagnostic testing from medical institutes and laboratories to the sites of patient care.  
Diagnostic testing conducted at or near the patient’s bedside is called point-of-care testing 
(POCT), which can be operated by patients themselves, caretaker or healthcare professionals 
outside of the clinical laboratory. In addition, POCTs allow test results to be read out facilely and 
quickly, which assists in making clinical management decisions in an immediate and timely 
manner.2 There is an increasing need of POC diagnostics, the corresponding expenses are 
projected to reach USD 38.13 Billion by 2022 from USD 23.71 Billion in 2017. Nowadays, the 
most widely applied POC device is blood glucose test strip, which was proposed in 1962 and 
bolstered by a portable pregnancy test strip in 1977.3 Since then, numerous paper-based lateral 
flow strips (PLFSs) has been developed for drugs screening, food pathogens screening and 
infectious disease testing. Most of the testing samples are human fluids, such as whole blood, 
serum, plasma, saliva and urine, which are easy to be collected and can provide diverse sensing 
pathways in a less-invasive mode. The underlying mechanism of a PLFS is based on sensing of a 
target molecule or biomarker. For example, a pregnancy test strip is manufactured for detecting 
human chorionic gonadotrophin (hCG) from urine sample, which is a protein biomarker relating 
with the pregnancy progression.4 In a typical pregnancy test, the urine sample is firstly collected 
into a container. And then the sample is moved from the container to the sample area of the 
pregnancy test strip through a dropper. By capillary force, the specimen flows from the sample 
area to the detection area. If hCG is present in the specimen, it will react with the conjugated 
NPs, which binds to the hCG-antibody on the detection area to generate a colored band. Presence 
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of two colored bands, which are respectively located at the detection area and control area, 
indicating a positive result; while the absence of the band located at the detection area indicates a 
negative result. The test procedure can be completed generally within 20 min. However, there are 
tradeoffs. In order to simplifying and reducing the cost, the sensitivity and accuracy of a PLFS 
are always sacrificed. As a result, most of the current PLFSs rarely deal with early-stage 
biomarker detection, owing to the fact that early stage diseases always relate with trace amounts 
of biomarkers. In addition, a relative large quantity of interference molecules existing in human 
fluids decreases sensing specificity and reduce signal accuracy of the devices. Therefore, it is of 
great significant to develop PLFSs with elevated performances to address the unmet need for 
sensitive and reliable measurement of early-stage biomarker from human fluids.  
1.2 OBJECTIVE 
In this dissertation, the objective is to address the problems and develop a sensitive, portable 
and low-cost sensor platform towards POC applications for early-stage biomarker detection in 
human fluids. To meet the demands, the following objectives are of paramount importance: 
1) The developed sensor should be portable, easy-operated and low-cost;  
2) The proposed device should address the limitations of current PLFSs, in terms of 
sensitivity, specificity and anti-interference ability; 
3) The proposed sensor platform should show promises as a real POC tool for practical 
applications. 
1.3 SIGNIFICANCE 
There is an increasing need of employing POC tools for early-stage disease monitoring. 
However, most of the reported biosensors suffer from low sensitivity and poor anti-interference 
capacity towards non-specific interference biomolecules in complex human fluids, which limit 
their applications in early stage disease detection. Therefore, my research aims to fill the gaps 
and overcome those challenges to fabricate viable and portable biosensors with high sensitivity 
and anti-interference capability. 
The proposed research is significant in that: 
1) It demonstrates the limitations and gaps between the existing state-of-the-art biosensors 
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and the desired POC tools; 
2) It proposes innovative approaches and sensing mechanisms to address the challenges of 
PLFSs; 
3) The proposed approaches and sensing mechanisms can be adapted to other applications, 
exhibiting transformative potential of the work. 
As a result, the developed PLFS in this dissertation enables direct disease biomarker detection 
from clinical plasma samples and whole blood samples. In addition, the obtained data from the 
developed PLFSs was comparable with that from the clinical standard ELISA method, exhibiting 
great promises as potential POC tools for practical applications.  
1.4 INNOVATION 
Several innovative strategies have been proposed in this dissertation to address the issues 
arose from current PLFSs, including:  
1) Ultrasensitive detection was realized through employment of surface-enhanced Raman 
scattering (SERS) technique and fluorescent technique into PLFS; 
2) The interference from non-specific biomolecules from human fluids was reduced by tuning 
optical property of nanomaterials to the biological transparent window; 
3) The anti-interference ability of the functional nanomaterials was improved through coating 
nanomaterials with silica layers, which can serve as a barrier to NPs from the interference 
biomolecules in human fluids; 
4) The interference of red blood cells (RBCs) from whole blood was reduced via modifying 
PLFS with plasma separation unit (PSU); the separation efficiency and separation rate was 
substantially elevated through employing functional chemicals;  
6) Signal amplification strategy of nuclease modification was introduced into PLFS for 
improving signal intensity and sensitivity. 
The reason for choosing SERS technique and fluorescent technique to modify PLFS is owing 
to the fact that they can offer LFTS with substantially elevated signal intensity and detection 
sensitivity. Moreover, compared with SERS technique, fluorescent technique exhibits an 
additional advantage in simplicity during signal acquisition.  
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1.5 OPERATION PRINCIPLE OF TEST STRIP 
PLFSs have been developed for analyzing target analytes within particular fluids beginning in 
the late 1970s with the advantages of simplicity, low cost, portability and instantaneous diagnosis 
in the proximity of the patients. After that, PLFSs have been widely used in biomedical 
applications, environmental monitoring, food safety, and clinical diagnosis for detecting various 
biomolecules and chemical contaminants, including infectious agents, nucleic acids, proteins, 
cells (i.e. cancer cells), veterinary drugs, and toxins. The most well-known applications of PLFSs 
are glucose test strips and pregnancy test strips.  
A general PLFS consists of a series of chromatographic pads containing dry reagents which 
can be activated by the fluid samples. Each chromatographic pad possesses different capillary 
properties and capacity in order to transport fluid smoothly and efficiently. A PLFS contains four 
chromatographic pads, including the sample pad, conjugate pad, nitrocellulose membrane and 
absorption pad. Details about each component functions as well as the assembly of the PLFS are 
listed below and illustrated in Figure 1.1. 
Sample pad: It is used to promote and distribute the sample fluid to the conjugate pad evenly. 
In this dissertation, cellulose fiber (17 mm × 30 cm, Millipore) was employed as the sample pad.  
Conjugate pad: It is made from glass fiber. The glass fiber can easily adsorb aptamer, DNA or 
antibody labeled nanoparticles (signal reporters). In this dissertation, glass fiber of 8 mm × 30 
cm was utilized.  
Nitrocellulose (NC) membrane: The most important component of the PLFS is the NC 
membrane. The pore size and the material properties of the membrane influence the flow rate 
(reaction time), the binding stability and the width of the test zone as well as the sensitivity of the 
entire system. In this dissertation, the NC membranes with the dimensions of 25 mm × 30 cm 
and pore size of 0.22 μm and 0.45 μm were employed. 
Absorption pad: The function of the absorption pad is to adsorb the excess fluid from the 
device while acting as a sink. Capillary effects draw fluid through the NC membrane from the 
sample pad into the absorption pad, maintaining constant motion until an equilibrium in capillary 
pressure is achieved. Therefore, the absorption pad enables more target analyte contained sample 
fluid to be extracted and detected over an increased time interval, leading to an improved 
sensitivity. In this dissertation, cellulose fiber with the dimensions of 17 mm × 30 cm was used 
as absorption pad.  
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Assembly of the PLFS: The sample pad, conjugate pad, NC membrane and absorption pad 
were laminated to a plastic adhesive backing layer (60 mm × 30 cm, Millipore). Each component 
was overlapped by 2 mm to ensure the migration of liquid throughout the PLFS. The mounted 
paperboard was cut lengthways and divided into individual PLFS with a 3-mm width by a 
guillotine cutter and then stored in a dry state. In a typical assay, a certain amount of sample 
solution is loaded onto the sample pad of a PLFS. Subsequently, the sample solution migrates by 
capillary action and successively passes the conjugate pad, NC membrane and finally arrived at 
the absorption pad. 
 
Figure 1.1. Schematic illustration of a blank PLFS. 
 
The mechanism of a PLFS is based on the combination of signal reporting and interfacing 
biological recognition events between biorecognition molecules, such as the interaction between 
an antibody with an antigen. On conjugate pad, detection reagents are immobilized, which 
contains detection biomolecules labeled signal reporters. On test zone and control zone, capture 
reagents and control reagents are respectively functionalized. There are two most frequently 
employed interaction formats for capturing target analyte on the detection zone of a PLFS: 
competitive format assay and sandwich format assay. Their corresponding response is inversely 
proportional to and proportional to the concentration of the analyte respectively. The competitive 
format works best for the target molecules with low molecular weight or presenting single 
specific antigen. The competitive format contains two sensing mechanism: 1) antibody coated 
format (Figure 1.2b): the competition between target antigen and signal reporter linked antigen. 
In this format, the specific antibody is firstly immobilized on the test zone. During the detection, 
the target antigen and signal reporter labeled antigen would compete for binding on the specific 
antibody on the test zone; 2) antigen coated format: the competition between antibody/signal 
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reporter and the complex of antigen-antibody/signal reporter (Figure 1.2c).  The target analyte 
contained sample solution is firstly incubated with the specific antibody/signal reporter to form 
the antigen-antibody/signal reporter. The resulting complex would compete with antibody/signal 
reporter for binding on the specific antigen immobilized test zone. Besides the above mentioned 
competitive format, another format is sandwich structure based format. In this format of assay, 
detection antibody is firstly functionalized with signal reporters; while the capture antibody is 
immobilized on the test zone. As shown in Figure 1.2a, during the detection, a sandwich 
structure of antibody-antigen-detection antibody/signal reporter is formed on the test zone of the 
PLFS. On the control zone of the PLFS, it is immobilized with secondary antibodies, which is 
employed for capturing the excess detection reagents from the test zone.  The control line is 
utilized to indicate that the test strip functions properly. 
 
 
Figure 1.2. Schematic illustration of the operation principle of sandwich format assay (a) and 
competitive format assay with antibody coating type (b) and with antigen coating type (c).   
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1.6 STRATEGIES FOR IMPROVING TEST STRIP PERFORMANCES  
Nanomaterials possess unique properties, such as large surface area, excellent 
biocompatibility, outstanding conductivity and catalytic ability. Employment of nanomaterials 
exhibits great promise in elevating sensor performances. For example, the electron transfer rate 
can be elevated from 700 to 5,000 when gold nanoparticles (GNPs) were immobilized into a 
biosensor.5 In addition, in an enzyme labeled biosensor, nanomaterial modifications can offer 
diverse microenvironment and more freedom of orientation for enzymes.6 Moreover, the stability 
of enzymes can be improved when enzymes were linked with GNPs.7 The properties of 
nanoparticles strongly depend on their size and morphology.8 For example, in aqueous solution, 
spherical GNPs with an average diameter of 20 nm exhibit strong absorption at ~ 520 nm in 
wavelength, which makes the GNPs present red color. While the GNPs start to aggregate, the 
absorption peak shifts to longer wavelength and the color of the GNPs changes to blue 
correspondingly. This unique property brings about many developments of binding-induced 
aggregation sensors.9 In a PLFS, GNPs are the most extensively employed signal reporters 
owing to their inherent advantages, including intense optical properties, vivid color and 
biocompatibility. In addition, the optical properties, size and morphologies of GNPs can be 
simply adjusted by changing the ratio between the reductant (sodium citrate) with HAuCl4, 
offering PLFS with diverse designs and developments for different sensing demands.10  The 
detection sensitivity of GNPs tagged PLFSs can be further elevated through nanoparticle-
promoted precipitation of gold or silver around GNP tags. Such precipitation enlarged the size of 
the NP-tags and enhanced the optical intensity of the test line, which amplifies the events of 
biorecognition, meanwhile benefits the colorimetric signal readout, leading to an elevation in 
detection sensitivity.11 Another effective approach for improving the GNP-PLFS sensitivity is to 
co-label enzyme onto GNP surfaces and then introducing enzyme substrates for amplifying 
signals. The most commonly used enzyme and enzyme substrate in PLFS is horseradish 
peroxidase (HRP) and TMB/H2O2. In a typical assay, after the HRP labeled GNPs are captured 
on the test area, the substrate TMB/H2O2 is introduced to improve the test line intensity. 
Compared with the conventional PLFS, the enzyme functionalized PLFS can realize one to two 
orders of magnitude improvement in detection sensitivity.12  Besides HRP, glucose oxidase and 
alkaline phosphatase are also the good choices for enzyme catalytic amplification. Polymerase 
chain reaction (PCR) is an effective approach for amplifying DNA concentrations with thousands 
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to millions of more copies of that particular DNA segment. Modifying and integrating the 
polymerase reactions into PLFSs can significantly improve the detection sensitivity.  A new 
strategy called strategy isothermal strand-displacement polymerase reactions (ISDPR) was 
developed and integrated into PLFSs to overcome the disadvantages of PCR. Compared with 
conventional PCR, no thermal cycling is required in the ISDPR-PLFS. In addition, the 
amplification procedure was significantly shortened to less than half an hour.13  
Besides GNPs, magnetic nanoparticles, microparticles, fluorescent dyes and quantum dots 
have also been employed into PLFSs as signal tags. The use of magnetic beads can offer the 
PLFSs with improved sensitivity. Since the noise from nonspecific adsorption was reduced by 
the magnetic separation procedure, while the signal was elevated owing to the large surface area 
of magnetic beads. Fluorescence techniques have been extensively applied in biological sensing 
on PLFS. Their performances are largely dependent on the physicochemical properties of the 
employed fluorophores. Several experimental parameters should be taken into account when 
choosing a fluorophore, including excitation and emission spectra, fluorescence intensity, 
lifetime and emission anisotropy. Organic dyes are often used as the fluorophores in biological 
research owing to their small sizes, which are suitable for conjugation with biomolecules. 
Additionally, various dyes with characteristic excitation and emission spectra are commercially 
available and the corresponding protocol for functionalization is well established. However, the 
photobleaching, narrow excitation spectra and low luminescent restrict their further applications.  
The employment of quantum dots (QDs) into fluorescent biosensors can address these 
challenges and meet the demands of fluorescent research owing to their unique properties, 
including resistant to photobleaching (fluorescence lifetimes: 1-10 ns vs 10-100 ns), size-
dependent emission, narrow emission bandwidths and high levels of brightness.14 For example, 
the values of molar absorption coefficients at the first absorption band of QDs are generally 
larger than the organic dyes (100,000–1,000,000 M–1 cm–1 vs 25,000–250,000 M–1cm–1); while 
the quantum yields are 0.1–0.8 (visible), 0.2–0.7 (near-infrared (NIR)) from QDs and 0.5–1.0 
(visible), 0.05–0.25 (NIR) from organic dyes. Additionally, with the light illumination, QDs can 
emit light of specific frequencies. The emission frequencies can be precisely tuned by changing 
the sizes and components of QDs, which offers QDs the flexibility for multiple detections with 
different emission peak positions.15 Lin’s group reported a QDs based fluorescent PLFS for rapid 
(10 min) detection of protein in both aqueous solutions and spiked human plasma samples.16 The 
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quantification for target protein was based on recording the fluorescent intensity of QDs that 
were captured on the test zone of PLFS through the specific biorecognition between antigen and 
antibody. LODs for target protein of 1 and 8 ng/mL were obtained from aqueous solutions and 
spiked human plasma samples respectively. This QDs based fluorescent test strip can be 
extended for the fast and simple analysis of other protein biomarkers.  
Recently, NIR nanomaterials attract increasing attention in bioassays due to that the biological 
tissues are highly transparent to the NIR light (700 to 1,100 nm). Studies showed that various 
nanomaterials present optical absorbance in this special NIR spectral window, such as NIR-QDs, 
SWNTs,17 graphene dots,18 and upconversion-luminescent phosphors (UCPs).19 Among the NIR 
NPs, QDs exhibit flexibility for multiple detections; while carbon nanomaterials and UCPs show 
low toxicity to biological samples, which are well suited for biomolecule analysis. As a result, 
the employment of NIR into PLFS shows an increase in sensitivity and anti-interference capacity 
in biological fluids compared with that of the conventional GNP-PLFSs.  
Signal quantity system is also crucial for improving PLFS performances, owing to the fact 
that proper signal recording approach can avoid signal loss, meanwhile generate stable signal 
responses, leading to the elevation of sensitivity and stability of a biosensor. In general, signal 
recording system is selected according to the employed signal reporters. For example, a 
colorimetric strip reader is designed for recording the color intensity from the test line of a GNP 
labeled PLFS; while a fluorescent strip reader is designed for recording the fluorescent signal 
from the test line of a QDs, fluorescent dye or UCPs functionalized PLFS. Recently, a concept of 
thermal contrast was proposed into the PLFS as the signal quantity system for improving the 
signal intensity and detection sensitivity.20 A laser/light emitting diode (LED) and an infrared 
temperature gun were employed instead of the conventional strip reader as the signal quantity 
system. The light was used to irradiating the GNPs captured on the test line while the infrared 
temperature gun was employed to record the thermal contract from the heated GNPs. As a result, 
this thermal contract mechanism endowed the GNP-PLFS with an improvement of 32-fold in 
detection sensitivity. The performance can be further improved through the employments of 
higher-absorbing NPs and low-absorbing PLFS backing materials.21    
The capacity of simultaneous detection of multiple biomarkers is another important factor to 
elevate the sensor performances, since measurement of multiple biomarkers is considered as the 
most promising approach to reliable diagnosis or prediction of diseases. For example, the 
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detection sensitivity for ovarian cancer was improved from 65% to 74% and the detection 
specificity was elevated significantly from 52% to 94% when multiple protein biomarkers were 
analyzed.22 Moreover, compared with single detection, simultaneous detection offers additional 
advantages, including timesaving, reduced operations, cost and samples.23 Simultaneous 
detection in PLFS can be realized through dispensing capture reagents on different test line 
respectively; meanwhile functionalizing signal tags with different detection reagents towards 
specific target biomolecules. In general, four test-lines is the maximum allowable dispensed 
amount on a PLFS according to the chemical reagent consumptions of a PLFS with general 
dimensions (3 mm × 60 mm). The signal tags functionalized detection reagents can be either 
mixed and then loaded on one conjugate pad of a PLFS, or loaded onto different conjugate pads 
of the multiple conjugate pads modified PLFS.  
In summary, the major advantages of PLFSs are portable, fast, low-cost and easy-operated.  
However, most of the current state-of-the-art PLFSs can only function in buffers or artificial 
solutions. It is still a formidable challenge to apply them in real applications owing to the relative 
low sensitivity, which cannot meet the demands for detecting early stage of disease biomarkers. 
Additionally, the high interference of nonspecific biomolecules in complex human fluids 
dramatically affects the sensing specificity and stability. By taking the advantages of explosive 
development of nanotechnology, many advanced techniques and strategies can be employed to 
solve the problems.  
1.7 TECHNIQUE OF SURFACE-ENHANCED RAMAN SCATTERING 
Raman spectroscopy has been intensively explored in the applications of biological sensing 
and medical diagnostics. However, the Raman scattering is much weaker than the other optical 
techniques, which is considered to be the main hurdle for ultrasensitive measurement for relative 
low sample concentrations.  
Metallic nanomaterials possess unique optical properties that are related to the collective 
oscillation of free conduction electrons in nanostructures in resonance with the incident 
electromagnetic radiation. These nanostructured materials are capable of providing surface 
plasmon resonances (SPRs) and can be utilized in biosensing technologies based on the principle 
that the intensity and the position of SPR is sensitive to the changes in the dielectric properties 
(refractive index) in the vicinity of the plasmonic surfaces. SPR occurs in two different forms: 
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propagating surface plasmon polaritons (SPPs) and localized SPR (LSPR). SPPs are the charge 
oscillations associated with an electric field propagating along a metal-dielectric interface. These 
oscillations are decaying exponentially in the perpendicular direction. LSPR occurs when the 
dimensions of a metallic nanostructure are much smaller than the incident wavelength, leading to 
non-propagating local oscillations of the plasmons around the nanoparticles. By utilizing 
plasmonic materials, numerous nanostructures have been developed as signal amplifiers for 
sensitive optical sensing. Surface-enhanced Raman scattering (SERS) is a powerful technique 
that possesses ultra-sensitivity by amplifying the Raman scattering signal by orders of magnitude 
if a molecule is associated to the surface of plasmonic nanomaterials.24 The most widely 
employed SERS-active metals are Au, Ag and Cu. The Raman signal enhancement of SERS is 
attributed to two mechanisms: chemical enhancement and electromagnetic (EM) enhancement. 
The chemical enhancement (10-100 enhancement factor) contributes to the electron interaction 
between the metallic substrate and the molecule absorbed on its surface; while the 
electromagnetic enhancement (104 and 1012 enhancement factor) induces the dominant 
contribution and it arises from the light-induced collective oscillation of conduction electrons 
from the metallic substrate.25 During developing of a biosensor, the SERS-active nanomaterials 
can be integrated as labels or patterned substrates.  
“Hot spots” are generated inside the gaps or around the sharp edges, corners or tips of the 
SERS-active nanomaterials, where the EM field is particularly intense, leading to extraordinary 
enhancement of SERS signal. Nowadays, a SERS enhancement factor of 1014 have been 
achieved through precisely fabricating the nanostructure, which is capable of sensing single 
molecule.26 SERS is also well-suited for multiple detections because of the “fingerprint” feature 
to produce distinct spectra from components in multiplexing. On the other side, this “fingerprint” 
ability can also increase the anti-interference resistance to nonspecific molecule in complex 
sample matrices. Therefore, SERS technique is well-suited to be used for ultrasensitive 
measurement in biological matrices.  
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Figure 1.3. Structure of sandwich typed SERS probe with SiO2 coating.  
 
Conventional SERS biosensors are developed using bare GNPs, which supports localized 
surface plasmon resonance (LSPR) for the absorbed Raman molecule to generating SERS signals. 
However, bare GNPs-based SERS probes are unstable in aqueous solutions with high ionic 
strength or in blood samples, which raises serious concern about reliability and robustness. In 
addition, the SERS labels are easy to desorb from the nanoparticle surface, leading to reductions 
of stability and signal intensity during the detection. A solution to this issue is to coat the SERS 
labels adsorbed nanomaterials with a thin protecting layer, such as polyethylene glycol (PEG) or 
SiO2 to form a sandwich-typed SERS label. The protective layer has several advantages: (i) it 
encapsulates numerous Raman reporters into a single particle, which enhances the SERS 
response; (ii) the protecting layer avoids the leaking out of Raman reporters, which increases the 
signal stability; (iii) it offers the capability for further surface-functionalize with biomolecules; 
(vi) it makes the nanoparticles water-soluble and biocompatible.  In this dissertation, Au nanostar 
will be employed as the SERS substrate for the absorbed Raman molecule to generating a strong 
plasmonic field foe amplifying SERS signal. While the Raman reporter molecules are 
sandwiched between an Au nanostar and a thin silica shell. This structure prevents Raman 
reporter molecules from leaking out. The Au nanostar generates a strong plasmonic field for 
amplifying SERS signal. The silica shell not only provides a platform for bioconjugation but also 
makes the SERS probe water-soluble. The structure of the sandwich typed SERS probe is 
illustrated in Figure 1.3.  
1.8 TECHNIQUE OF NEAR-INFRARED FLUORESCENCE (NIRF) 
Fluorescence techniques have been extensively applied in biological sensing, cell imaging and 
screening. Their performances are largely dependent on the physicochemical properties of the 
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employed fluorophores. Several experimental parameters should be taken into account when 
choosing a fluorophore, including excitation and emission spectra, fluorescence intensity, 
lifetime and emission anisotropy.27 Organic dyes are often used as the fluorophores in biological 
research owing to their small sizes, which are suitable for conjugation with biomolecules. 
Additionally, various dyes with characteristic excitation and emission spectra are commercially 
available and the corresponding protocol for functionalization is well established. However, the 
photobleaching, narrow excitation spectra and low luminescent restrict their further 
applications.28 
The employment of near-infrared fluorescence (NIRF) attracts increasing attention in 
biological applications owing to that it can reduce the damage of biological samples and avoid 
the photobleaching and background interference when visible fluorophores (VisF) are utilized.29 
This is because that due to reduced absorbance and minimal scattering, the NIR radiation 
possesses high penetration ability towards tissues and biological matrices. Meanwhile, the NIR 
wavelengths falls within the biological windows with low background fluorescence signals, 
which provides elevated signal-to-noise ratio.30 In this dissertation, NIRF dye-encapsulated silica 
nanoparticles have been developed. The superior properties of such nanoparticles include 
amplified signal, outstanding photostability, water-solubility and viability of surface 
modification. For example, the silica layer enables a large number of NIRF dye molecules to be 
encapsulated inside of one single silica nanoparticle, which can dramatically magnify its 
luminescence signal. In addition, the external silica layer protects the dyes from the surrounding 
matrix or other environment, which minimizes the photobleaching phenomena and increases its 
photostability. Moreover, silica possesses flexible routes for surface modifications with various 
types of functional groups (e.g. –NH2, -COOH, -SH), which allows its conjugation with different 
biomolecules during bioassays.31  
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Chapter 2: SURFACE ENHANCED RAMAN SCATTERING TEST STRIP 
FOR PLASMA TESTING 
2.1 TRMATIC BRAIN INJURY 
Traumatic brain injury (TBI) is a leading cause of death and disability in both the United 
States and the developed world. Approximately 2.8 million TBI-related emergency department 
(ED) visits, hospitalizations and deaths occurred in the United States in 2013. The estimated 
direct and indirect medical costs of TBI were estimated to be in excess of $76 billion in 2010. 
The current ED standard of care for the initial assessment of a patient’s potential TBI includes 
employment of the Glasgow Coma Scale (GCS), in which a clinician numerically assesses the 
brain impairment based on the bedside physical examination, and computed tomography (CT) 
scans. These screening tools are presently used for initial clinical management and prognosis of 
TBI.32 However, they cannot provide information on pathophysiological processes, and they are 
not very sensitive or specific, particularly in the case of mild or moderate TBI. On the other hand, 
some ED patients with traumatic injuries and a poor GCS are subject to brain impairment due to 
intoxication from alcohol and/or drugs instead of from a true brain injury. Although early CT 
scans are useful for detection of intracerebral hemorrhage, they are often less effective at early 
detection of the more common cerebral contusions and diffuse axonal injury. Additionally, there 
has been a growing concern regarding radiation exposure from the use of screening CT scans in 
patients with possible TBI. Magnetic resonance imaging (MRI) is much more sensitive for 
detecting early TBI and does not expose patients to radiation. However, these studies are 
expensive and time-consuming, often require patient sedation, and are frequently unavailable at 
the ED.33 Early and accurate diagnosis of TBI is clinically important, as currently routine yet 
potentially unnecessary screening imaging might be avoided. Additionally, many patients with 
even mild TBI may experience short- or longterm sequelae including changes in attention and 
memory and emotional disturbances that may benefit from early diagnosis and intervention. 
Importantly, TBI clinical trials such as those testing potential early therapies aimed at, for 
example, decreasing secondary injury have been severely hampered by the dilemma of early 
diagnosis of true TBI as opposed to intoxication, with this “noise” requiring an increase in 
sample size and expense, and possible dilution of the measurable effect of the potential therapy. 
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Measurement of protein biomarkers can provide an alternative route for rapid and accurate 
disease diagnosis. Protein biomarkers are present in human fluids, such as blood, saliva, or urine, 
which makes the tests much less invasive, rapid, and inexpensive and avoids the radiation 
involved with CT scans and time, sedation, and expense of MRIs.  
The most common TBI biomarkers are glial fibrillary acidic protein (GFAP), S100-β, and 
neuron-specific enolase (NSE), which are released into circulation after the brain damage 
occurs.34 Several methods have been employed to measure the protein biomarkers, including 
enzyme-linked immunosorbent assay (ELISA), Western blot, and agarose. However, those 
methods generally involve time-consuming operation processes and large sample volume and 
require expensive instruments, which cannot be used as the point-of-care (POC) analytical tools 
for rapid and low-cost clinical diagnosis. Therefore, great efforts have been devoted to 
developing portable biosensors toward POC testing. Recently, several biosensors have been 
employed for NSE biomarker detection, including electrochemistry,35 chemiluminescence,36 and 
field-effect transistor.37 However, most of these biosensors were tested in buffer solutions and 
did not demonstrate the direct detection of NSE biomarker in human fluidic samples. Moreover, 
many biosensors still need multiple steps of operation in vials, which are not user-friendly. 
Hence, it remains a challenge for those sensors to be used in a POC setting. 
PLFSs have received increasing attention as POC tools because they are inexpensive, user-
friendly, and easy to operate.38 Colorimetric,12 fluorescent,16 and electrochemical39 transducers, 
are commonly used in PLFS. Unfortunately, they usually suffer from poor sensitivity and serious 
interference from sample matrices when they are used in blood plasma samples. In contrast, 
surface enhanced Raman scattering (SERS) has strong anti-interference ability in real-world 
samples because the wavelengths of both the excitation light and the scattering Raman signals 
can be tailored into the near-infrared biological transparency window, and Raman spectra are 
characteristic of fingerprint signatures of target molecules.40 Several papers have recently 
reported the incorporation of SERS transducers into PLFS for detection of proteins and nucleic 
acids in water or buffer solutions. In these reported SERS-PLFS, bare Au nanoparticles were 
used as the SERS substrates.41 Bare Au nanoparticle-based SERS probes are unstable in aqueous 
solutions with high ionic strength or in blood samples, which raises serious concern about 
reliability and robustness.42 Hence, the SERS-PLFS based on bare Au nanoparticle have not been 
applied to blood samples yet. To address the instability issue of bare gold nanospherebased 
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SERS probes, Au nanostar@Raman Reporter@silica sandwich nanoparticles have been 
developed as the SERS probes in our research group, in which the Raman reporter molecules are 
sandwiched between an Au nanostar and a thin silica shell. This structure prevents Raman 
reporter molecules from leaking out. The Au nanostar generates a strong plasmonic field for 
amplifying SERS signal. The silica shell not only provides a platform for bioconjugation but also 
makes the SERS probe water-soluble. Our previous study has shown that these types of 
sandwich SERS probes are very stable in aqueous solutions with high ionic strength while bare 
Au nanoparticles tend to aggregate under the same condition. In the present work, the sandwich 
SERS probes are incorporated into a PLFS to detect the NSE biomarker in blood plasma. By 
comparison, a colorimetric PLFS with bare plasmonic Au nanospheres is also used for protein 
detection. Compared to the colorimetric PLFS, the SERS-based PLFS shows much higher 
sensitivity in blood plasma samples. To the best of our knowledge, this report for the first time 
demonstrates the successful detection of protein biomarkers in clinical blood plasma samples 
using a SERS-based PLFS without any purification or separation procedure. The results show a 
great potential of SERS-PLFS in the POC setting.  
2.2 MATERIAL AND METHODS 
2.2.1 Reagents and Materials  
Malachite green isothiocyanate (MGITC) was purchased from Molecular Probes, Inc. 4- 
Mercaptobenzoic acid (technical grade, 90%) (4-MBA) was purchased from Sigma-Aldrich. 3-
Triethoxylsilylpropyl succinic anhydride (TEPSA) was obtained from Gelest Inc. 
Nhydroxysuccinimide (NHS), 1-ethyl-3-(3-(dimethylamino)- propyl) carbodiimide (EDC), and 
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, sucrose, 
Na3PO4·12H2O, Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), BSA (bovine serum 
albumin) and sodium chloride were acquired from Sigma-Aldrich and used without further 
purification. Sucrose was purchased from VWR. Goat antihuman IgG polyclonal antibody, mice 
antigoat IgG polyclonal antibody, IgG from human serum, Neuron-specific enolase from human 
brain (NSE), and antineuron-specific enolase antibody were procured from Sigma-Aldrich. 
Neuronspecific Enolase Quantikine ELISA Kits were purchased from R&D System and Eagle 
Bio. The blood plasma was purchased from US Biological Life Science (P4252-56 Plasma, 
Human, IgG Free). Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), 
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laminated cards with Hi Flow plus cards (HF090MC100 with RK12312 Membrane (0.45 μm)), 
and nitrocellulose membrane (RK13464 (0.22 μm)) were purchased from Millipore (Billerica, 
MA). Clinical blood plasma samples were collected from TBI patients presenting to the ED as 
part of the Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen pilot clinical 
trial for traumatic brain injury (RESCUE-TBI) conducted by researchers at the University of 
Texas Southwestern Medical Center and Parkland Hospital. As part of this study, the clinical 
samples were serially collected at various time points over the first 5 days following TBI and 
stored at −80 °C prior to measurement. All work conducted in the pilot clinical trial was 
approved by the National Heart, Lung, and Blood Institute’s Resuscitation Outcomes 
Consortium Protocol Review Committee and Data Safety Monitoring Board, the U.S. Food and 
Drug Administration, and the University of Texas Southwestern Medical Center Institutional 
Review Board. Use of these deidentified human samples at West Virginia University was 
approved by the West Virginia University Institutional Review Board. 
2.2.2 Instruments and Characterization  
All Raman spectra were acquired with a portable B&W Tek i-Raman Plus. Fourier transform 
infrared (FT-IR) spectra were obtained under the attenuated total reflection (ATR) mode with 
Thermo Nicolet 6700 spectrometer. The nanoparticles were characterized with a transmission 
electron microscope (TEM, JEOL JEM-2100F) at an acceleration voltage of 200 kV. UV−visible 
absorption spectra were obtained with a Shimadzu UV-2550 spectrometer. 
2.2.3 Synthesis of Nanoparticles and Conjugation with Detection Antibodies  
The Au nanostars, the SERS probes, and the nanoparticles conjugated with detection 
antibodies were synthesized according to our previous paper.40 The preparation procedure is 
illustrated in Figure 2.1. Briefly, the Au nanostar@Raman molecule@Silica sandwich SERS 
probes were synthesized by adding 1.0 μM Raman molecules into the Au nanostar suspension. 
Then, 200 μL of 1% TEOS and 15 μL of ammonium solution were added into the mixture, 
successively. After the SERS probes were formed, the resulting solutions were centrifuged and 
resolved in 500 μL of ethanoic solution. The Au nanostars were coated with a 2−3 nm thick 
silica layer on the outer surface. Figure 2.2 shows the TEM images of the sandwichtyped SERS 
nanoparticles.  
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Figure 2.1. Schematic illustration of the preparation process of the SERS probe conjugated with 
the detection antibody. 
 
 
Figure 2.2. TEM images of the Au nanostar@MBA@SiO2 sandwich nanoparticles a) low 
magnification and b) high magnification. 
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Figure 2.3. UV-visible absorption spectra of the Au nanostar and the Au nanostar@Raman 
molecule@silica sandwich nanoparticles. 
 
 
Figure 2.4. FT-IR spectra of the carboxyl-group functionalized SERS probe. The peak at 1704 
cm-1 peak is assigned to the C=O stretching vibration in COOH of TEPSA. 
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Figure 2.5. FT-IR spectra of the detection antibody functionalized SERS probe. The peaks at 
1649 and 1551 cm-1: correspond to the N-H bending in the antibody. 
The coating of the silica layer was further approved by the UV−visible absorption spectra. 
That is, the localized surface plasmon resonance (LSPR) absorption band of the nanoparticles 
shifted from 770 to 790 nm after it was coated with silica (Figure 2.3). Next, 100 μL of TEPSA 
was added to the SERS probe solution and then incubated overnight to achieve the carboxyl-
groupterminated SERS probes. In the current study, the conjugation of carboxyl-group onto the 
surface of SERS nanoparticles was confirmed by FT-IR spectra (Figure 2.4). The carboxyl-
groupterminated sandwich nanoparticles were then activated by adding a PBS buffer solution 
containing 50 mM NHS and 200 mM EDC and then incubated for 1 h. Subsequently, 100 μL of 
1.0 mg/mL detection antibody was added, and the mixture was incubated overnight. After that, 
the mixture was centrifuged and washed with a PBS buffer three times to remove excessive free 
antibody. The resulting SERS probe conjugates were stored in 100 μL of eluent buffer (20 nM of 
Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) solution for future use. 
The successful conjugation of detection antibody onto SERS nanoparticles was confirmed by the 
FT-IR spectra (Figure 2.5). 
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Figure 2.6. Schematic illustration of the operation principle of SERS paper-based lateral flow 
strip (PLFS). (a) Top and side views; (b) side view before and after detection of protein 
biomarker; (c) optical photos of PLFS assembled in cassettes in the presence (upper) and absence 
(bottom) of the target protein. 
2.2.4 Preparation of Test Strip  
Figure 2.6 shows the schematic diagram of the PLFS, which consists of four components: a 
sample pad, a conjugate pad, a nitrocellulose membrane (NC membrane), and an absorbent (or 
wick) pad. All the components were mounted on a common backing layer (typically an inert 
plastic, e.g., polyester). The sample pad was saturated with a Tris-HCl buffer (pH 8.0) containing 
0.23% Triton X-100 and 0.05 and 0.15 M NaCl. The pad was then dried at 37 °C for 2 h and 
stored in a desiccator at room temperature (RT). Then, 200 μL of 2.5 mg/mL capture antibodies 
and secondary antibodies were dispensed onto the NC membrane by a homemade dispenser to 
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form a test line and a control line, respectively. The capture antibody and the secondary antibody 
were dispensed twice and once, respectively. The distance between the test line and control line 
was 3 mm. The membrane was then dried at 37 °C for 1 h and stored at 4 °C under a dry 
condition. Successful conjugation of antibody onto the NC membrane was confirmed by FT-IR 
spectra (Figure 2.7), in which the peak at 1534 cm−1 indicated the N−H bending. The SERS 
probes conjugated with the detection antibodies were dropped onto the conjugate pad. Finally, all 
the four processed components were assembled onto a plastic adhesive backing layer. The 
components were overlapped with 2 mm to ensure that the solution was able to flow through the 
whole strip. Each strip was cut to be 3 mm wide by a paper cutter (Swingline 12 in. ClassicCut 
Lite Trimmer). Before testing, 7 μL of SERS probes conjugated with the detection antibody was 
loaded onto the conjugate pad of PLFS. During testing, 100 μL of sample solution containing a 
certain concentration of analytes was dropped on the sample pad of PLFS. 
 
Figure 2.7. FT-IR spectra of the capture antibody functionalized NC membrane. The peak at 
1534 cm-1 is assigned to the N-H bending. 
2.3 RESULTS AND DISSCUSSION 
2.3.1 Operation Principle  
The prepared PLFS is a carrier device containing dry reagents that are activated by applying a 
fluid sample (Figure 2.6b). Once the sample solution containing analyte is dropped onto the 
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sample pad of PLFS, the solution will flow to the conjugate pad by the capillary force. On the 
conjugate pad, the target protein molecules interact with the SERS probes conjugated with 
detection antibodies to form a complex of target protein-detection antibodies labeled SERS 
probes. The resulting complex continues to move until it is captured by the capture antibody on 
the test line. At this moment, the SERS probes are accumulated on the test line through the 
formation of a sandwich-type configuration of SERS probe (linked with detection antibody)-
protein-capture antibody. The excessive SERS probes linked with detection antibodies continue 
to migrate and then are captured by the control line where the secondary antibody is immobilized. 
As a result, two greyish bands are displayed on the test line and the control line, respectively 
(Figure 1c). A portable Raman spectrometer is employed to record the SERS signal. Under 
excitation by a 785 nm laser, the SERS signal is generated from the MBA (Raman reporter) 
molecules inside of the SERS probes. As shown in Figure 2.8, the SERS spectra acquired from 
the test line are characteristic of both the Raman reporter and the NC membrane. The amount of 
SERS probes captured on the test line is in proportion to the concentration of a target protein, 
which is employed for quantification. In the absence of the target protein, only the control line 
shows greyish color, indicating that the test strip functions properly. 
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Figure 2.8. SERS spectra of the Au sphere@MBA@silica sandwich SERS probes on the NC 
membrane and Au film. 
 
2.3.2 Optimization  
In order to optimize the performance of the PLFS, it was used to detect 1 ng/mL of human 
IgG. The human IgG was selected as the model analyte because this protein is well-known, and 
its testing is much more inexpensive compared with NSE testing. In the optimization study, 
MIGTC was used as the Raman reporter initially, and the SERS spectra with a characteristic 
peak at 1173 cm−1 were recorded. The flow rate of the sample solution significantly influences 
the efficiency of binding between antibodies and antigens, as well as the signal intensity and the 
signal-to-noise (S/N) ratio. Generally, the flow rate of a liquid in the PLFS is dependent on the 
surfactant content and the pore size of the NC membrane. The surfactant in the running buffer is 
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an important component, which regulates the binding time between an antibody and its antigen 
and, meanwhile, mitigates the nonspecific adsorption of SERS probe on the test line. TWEEN 20 
was chosen as the surfactant, and its content in the running buffer was optimized. Figure 2.9a 
reveals that the S/N ratio of the SERS peak increased with the growing content of TWEEN 20 
content in the running buffer until it reached 0.07%. Further increase in the TWEEN 20 content 
led to a decrease in the S/N ratio, as a high TWEEN 20 content caused a high flow rate of 
running buffer, leading to a significant decrease in the binding time between the antibody and the 
antigen. Another parameter governing the flow rate is the pore size of the NC membrane. 
Reducing the pore size decreases the flow rate and increases the time of binding between the 
target analyte and the antibody. As shown in Figure 2.9b, the S/N ratio for small pores (0.22 μm 
in a diameter) was higher than that for large pores (0.45 μm). In addition, the signal intensity and 
the detection sensitivity are significantly affected by the detection antibody-linked SERS probe 
amount on the conjugation pad and the capture antibody immobilized on the test line because 
both of the factors affect the ability of PLFS to capture the antigen. As shown in Figure 2.9c, d, 
the optimal detection antibody-linked SERS probe amount was 7 μL, and two-time dispenses 
were the best.  
 
Figure 2.9 Optimization of the experiment conditions for SERS-PLFS. a) Effect of the surfactant 
TWEEN 20 content in the running buffer on the S/N ratio of PLFSs, b) effect of the membrane 
type (pore size) on the S/N ratio, c) effect of the volume of SERS-detection antibody conjugate 
on the S/N ratio, and d) effect of the dispensing time of the capture antibody on test line on the 
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S/N ratio. 
2.3.3 Performance of Test Strip 
A comparative study was performed on the use of two types of Raman reporters (MGITC and 
MBA). The SERS-PLFS with two different Raman reporters were used to measure various 
concentrations of human IgG in the PBS buffer. Figure 2.10 shows the MBA-SERS spectra and 
the corresponding calibration curve (Figure 2.10b). The overall SERS intensity obtained from 
the MBA-based PLFS (Figure 2.10a) was stronger, and the peaks were much sharper than those 
from the MGITCbased PLFS (Figure 2.10c). The calibration curve in Figure 2.10b was 
obtained by plotting the SERS peak intensity at 1076 cm−1 from MBA as a function of the 
logarithmic concentration of human IgG. The calibration curve in Figure 2.10d was obtained 
from the PLFS by recording the SERS peak intensity at 1173 cm−1 from MGITC. The slope of 
calibration curve for the MBA-PLFS was 15 times higher than that for the MGITCPLFS. The 
limit of detection (LOD) was determined at the signal-to-noise ratio of 3, which was 0.02 and 
0.05 ng/mL for the MBA-PLFS and the MGITC-PLFS, respectively. In short, the MBA-PLFS 
exhibited higher sensitivity and lower LOD than the MGITC-PLFS. Therefore, MBA was 
employed for analyte detection instead of MGITC in the following experiments. The 
reproducibility of the MBA-based PLFS was examined. Human IgG samples at three levels were 
tested, and five SERS spectra were acquired at each level of human IgG. The SERS peak 
intensity of MBA at 1076 cm−1 exhibited good signal reproducibility. The corresponding relative 
standard deviation (RSD) values of MBA peak intensities were 7.0%, 4.1%, and 5.9% for 
measuring 10, 1, and 0 ng/mL of IgG in PBS, respectively.  
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Figure 2.10. SERS spectra obtained from the SERS-PLFS with different Raman report 
molecules. (a) MBA as Raman reporter and the corresponding calibration curve (b); (c) MGITC 
as Raman reporter and the corresponding calibration curve (d). 
 
2.3.4 Measurement of Anti-Interference Ability in Blood Plasma. 
In order to study the anti-interference ability in real-world biological fluids, the developed 
SERS-PLFS was employed to measure the human IgG spiked in a PBS solution and in a mixture 
of 90% PBS and 10% blood plasma (a specially treated IgG-free blood plasma purchased from 
US Biological Life Science (P4252-56 Plasma, Human, IgG Free)), respectively. When the 
SERS-PLFS was used for detection of IgG in 100% PBS solution, the calibration curved showed 
a linear detection range from 0.5 ng/mL to 0.1 mg/mL (Figure 2.10b), achieving a LOD of 0.02 
ng/mL. When it was used to test a mixture of 90% PBS and 10% blood plasma, the calibration 
curve showed a linear detection range from 1.0 ng/mL to 0.05 mg/mL (Figure 2.11), achieving a 
LOD of 0.08 ng/mL. In addition, the slope of the calibration curve obtained from the mixture of 
90% PBS and 10% blood plasma (Figure 2.11) was much smaller than that from 100% PBS 
(Figure 2.10b). The results indicated that an abundance of biomolecules present in blood plasma 
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affected the binding of antibody to the target protein. 
 
Figure 2.11. Calibration curve of SERS-PLFS with MBA as Raman reporter for detection of IgG 
in a mixture of 90% PBS and 10% blood plasma. 
 
2.3.5 Comparison of Performance 
Comparative studies were performed on the colorimetric and SERS PLFS. The plasmonic Au 
nanoparticles acted as the sensing transducer in the colorimetric PLFS while the Au 
nanostar@MBA@silica sandwich nanoparticles served as the sensing transducer in the SERS-
PLFS. Figure 2.12a shows that the colorimetric PLFS worked well when it was used to measure 
IgG in the PBS solution. The calibration curve showed a linear range from 1 ng/mL to 50 μg/mL 
(Figure 2.12c), achieving a LOD of 0.5 ng/ mL. However, when the colorimetric PLFS was 
employed for IgG detection in a mixture of 90% PBS and 10% blood plasma, the color intensity 
of the test line was much weaker than that tested in a PBS buffer (Figure 2.12b), and a high 
LOD (50 ng/ mL) was observed. When the SERS-PLFS was used for detection of IgG in 100% 
PBS solution, a LOD of 0.02 ng/mL (Figure 2.10b) was achieved, which was 1 order of 
magnitude lower than that of the LOD (0.5 ng/mL, Figure 2.12c) of the colorimetric PLFS. In 
contrast, when they were applied to the sample matrix containing blood plasma, the SERS-PLFS 
(Figure 2.11) showed much better performance than the colorimetric PLFS (Figure 2.12c). The 
SERS-PLFS exhibited a LOD of 0.08 ng/mL, which was 3 orders of magnitude lower than that 
(50 ng/mL) of the colorimetric counterpart. This result demonstrated that the SERS-PLFS had 
much better antiinterference ability than the colorimetric counterpart when they were applied to 
the blood plasma sample matrix. 
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Figure 2.12. Optical photos and calibration curves of colorimetric PLFS for detection of IgG 
(0−50 μg/mL): (a) in PBS buffer and (b) in a mixture of 90% PBS and 10% blood plasma; (c) 
corresponding calibration curves. 
 
2.3.6 Measurement of Protein Biomarker in Diluted Blood Plasma. 
The SERS probe is the key to the SERS-PLFS. In our sandwich-structured SERS probe, the 
silica shell is vital to ensure the stability of the SERS probe in the real-world blood plasma that 
typically exhibits high ionic strength, as shown in our previous paper. Herein, the stability of the 
bare Au nanospheres, the silica-coated Au nanospheres, and the silicacoated Au nanostars in the 
diluted blood plasma was tested (see Figure 2.13). It was found that the color of the 80% blood 
plasma sample containing the bare Au nanosphere became darker after 6 h of incubation, and the 
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bare Au nanospheres were found to be aggregated at the bottom of the vial after overnight. In 
contrast, the color of the counterpart samples containing the silica-coated Au nanospheres and 
the silicacoated Au nanostar was not altered, and no aggregation was observed after overnight. 
This result indicated that the silica shell prevented the nanoparticles from aggregation in the 
diluted blood plasma.  
 
Figure 2.13. Stability test results of the bare Au nanospheres, the silica-coated Au nanospheres 
and the silica-coated Au nanostars. (a) nanoparticles in water; (b) nanoparticles in a mixture of 
80% of blood plasma and 20% buffer solution after sitting for 1 minute; (c) nanoparticles in the 
mixture after 6 hours; and (d) nanoparticles in the mixture after overnight. 
 
In the SERS probe, the Au nanostar is chosen as the core rather than the Au nanosphere 
because the Au nanostar can result in much higher SERS enhancement than the Au nanosphere.42 
This is due to the fact that the Au nanostar possesses a lot of “hot spots” and shows a LSPR band 
that is overlapped with the wavelength of excitation laser. Under the optimal experiment 
condition, the developed SERS-PLFS was employed to detect various concentrations of NSE 
biomarker spiked into a mixture of 20% PBS solution and 80% blood plasma. It is noted that 
measurement of NSE in a diluted blood plasma can be finished within 30 min. Prior to NSE 
measurement, the baseline concentration of NSE in the blood plasma was measured by a 
commercial NSE ELISA kit (R & D System). Three ELISA measurements were performed. 
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None of the tests showed any signal response, which indicated that the NSE content in blood 
plasma was lower than the LOD (0.038 ng/mL) of the ELISA Kit. Figure 2.14 shows that the 
intensity of SERS peak at 1076 cm−1 gradually rises with an increase in the NSE concentration in 
a mixture of 20% PBS and 80% blood plasma. The SERS peak intensity (y) versus the NSE 
concentration (x) was fitted as y = 6.7x + 275.3 with the relative coefficient (R2) of 0.98, 
showing a linear detection range from 1.0 to 75.0 ng/mL, achieving a LOD of 0.86 ng/mL. The 
LOD was estimated with three times the standard deviation of negative control divided by the 
slope of calibration curve. This LOD was below the cutoff value of NSE concentration (12.4 
ng/mL) in blood plasma of TBI patients. The NSE level in TBI patients generally is elevated 
to >21.7 ng/mL. Our experimental results show the SERS-PLFS developed in the present work 
can work for NSE detection in blood plasma. 
 
Figure 2.14. SERS spectra (a) and calibration curve (b) of SERS-PLFS with MBA as Raman 
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reporter for detection of NSE in a mixture of 20% PBS and 80% blood plasma. 
2.3.7 Measurement of Protein Biomarker in Clinical Blood Plasma Samples 
The calibrated SERS-PLFS was employed to measure the NSE biomarker level in clinical 
blood plasma taken from the TBI patients. The same clinical samples were also measured with 
the commercial ELISA kits to validate the measurement results obtained from the SERSPLFS. 
Figure 2.15 shows the NSE concentrations in six clinical blood plasma samples measured by the 
SERS-PLFS and the NSE ELISA kits (R & D System and Eagle Bio), respectively. The results 
reveal that the data obtained by the SERS-PLFS were comparable to those by the ELISA. This 
result is appealing because the SERS-PLFS has evident advantages over ELISA when applied to 
clinical blood plasma samples. The SERS-PLFS is easy to operate, which enables clinical blood 
plasma samples to be measured rapidly with a portable Raman spectrometer. The clinical impact 
of such an inexpensive and rapid bedside diagnostic tool stands to change practice in the 
diagnosis of TBI in both the clinical and research arenas through early, easy, and accurate 
detection of true TBI and will reduce the diagnostic radiation exposure, increase the accuracy of 
the diagnosis, decrease costs, allow for earlier interventions aimed at mitigating both short- and 
long-term sequelae, and improve the quality of TBI clinical trials.  
 
Figure 2.15. NSE concentrations in clinical blood plasma samples, which were measured by 
ELISA and the SERS-PLFS, respectively. 
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2.4 CONCLUSION  
In summary, a SERS-PLFS was successfully developed in the present work. The LOD of 
SERS-PLFS was 1 order of magnitude lower than that of the colorimetric PLFS when they were 
used for detection of proteins in PBS buffer but was 3 orders of magnitude lower in a mixture of 
PBS and blood plasma. This result proves that the SERS-PLFS had much better anti-interference 
capability and improved sensitivity in blood plasma-containing sample matrix compared to the 
colorimetric PLFS. The key to success of SERS-PLFS is the employment of the Au 
nanostar@Raman reporter@silica sandwich nanoparticles as the SERS probes. Such SERS 
probes have strong SERS enhancement capability, excellent stability in complex blood plasma 
matrix, and good ability of antiinterference. The SERS-PLFS achieved a linear detection range 
from 1.0 ng/mL to 75.0 ng/mL toward NSE in a mixture of 80% blood plasma and 20% PBS. 
The SERS-PLFS was successfully employed for detection of NSE in clinical blood plasma 
samples. Obviously, the SERS-PLFS has advantages over the ELISA approach, including low 
cost, portability, short operation time, and simple operation procedure. These merits endow the 
SERS-PLFS with great potential to be employed as a POC tool for monitoring the protein 
biomarkers in real-world blood samples. 
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Chapter 3: PLASMA SEPARATION UNIT IN WHOLE BLOOD TESTING  
3.1 BIOMARKER OF CARCINOEMBRYONIC ANTIGEN (CEA) 
A critical and challenging future direction in science and engineering is to develop 
technologies to improve the health of people in the developing and remote regions of the world.1 
However, advanced diagnostic technologies are always centralized and requiring sophisticated 
instruments, specialized laboratory personnel and expensive chemicals. Moreover, continuous 
and long term monitoring add tremendous time and financial burden on patients due to 
soaring costs and frequent travel to hospitals and institutions. These factors have accelerated the 
emphasis on the development of low-cost, easy-to-operated and reliable devices to shift 
diagnostic testing from medical institutes and laboratories to the sites of patient care.  
Paper-based devices appear to be effective tools for providing access to point-of-care (POC) 
applications, owing to their advantages of low cost, fast response, portability and ease of use.43 
In addition, paper is compatible with biological samples, which allows its application in 
analyzing various biomolecules during bioassay.44 Moreover, paper-based POC testing allows 
test results to be read out facilely and quickly, which assists in making clinical management 
decisions in an immediate and timely manner. The underlying mechanism of a paper-based POC 
device is mainly based on sensing of a specific target molecule or biomarker from human fluids, 
such as blood, serum, plasma, saliva and urine, which are easy to be collected and provides 
diverse sensing pathways in a less-invasive mode. Nevertheless, issues arise from poor 
sensitivity and the interference biomolecules from the complex human fluids, especially red 
blood cells (RBCs) from whole blood samples. For example, paper substrates are easy to be 
visibly contaminated with the strong red color from RBCs, which leads to imprecise testing 
results, particularly when the tests are carried out in colorimetric based assays. Additionally, the 
aggregation of erythrocytes in the optical detection zone can substantially decrease signal 
quality.  In order to wash away the aggregates on the test area, extra washing steps are required, 
which increases sample-to-answer times. Moreover, most of the clinical biochemical tests are 
normally operated in the liquid portion of blood without cells, such as blood serum or plasma. 
Thus, separating RBCs from whole blood is necessary and it is also crucial to elevating the 
performances of sensors. Conventional separation strategies, such as mechanical forces, electro-
osmotic flow, dielectrophoretic techniques and magnetic interactions, can only be carried out in 
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controlled central laboratories or care centers, where are equipped with sophisticated instruments 
and specialized laboratory personnel.45 Thus, significant effort has been devoted into the 
development of low-cost and easy-to-operated approaches, which has resulted in the rapid 
development of miniaturized devices. Recently, several research groups have developed 
aggregation based approaches, which allows the interception of RBCs, meanwhile enables the 
separation of plasma from whole human blood samples on paper devices.46 The principle of this 
method is to develop RBC aggregations, which size is too large to pass through the pores within 
the fiber network of paper. For instance, a specific interaction between antibody and antigen was 
utilized to trigger RBC haemagglutination inside of the fiber network of paper. However, this 
method is only capable of separating RBCs from blood samples of types A, B, AB and O Rh 
positive, which requires blood typing before operations. In addition, antibody immobilized 
papers require critical fabrication and storage conditions, which increases costs of such devices. 
Another method was developed based on introducing salt solutions to achieve the goal of 
aggregating RBCs from whole blood samples. The basic mechanism is based on destabilizing 
RBC suspension through suppressing the electric double layer on the surface of RBCs; 
meanwhile generating of osmotic pressure, which causes RBCs to change morphologies, leading 
to close packing and formation of RBC aggregations. As a result, plasma moves forward by itself 
in the fiber network through capillary force.47 However, this method is difficult to be employed 
into nanoparticle functionalized paper devices, since the high ionic strength from salt solutions 
also induces the aggregation of nanoparticles, which leads to inaccurate signal responses and 
decreased sensitivity. Recently, our research group developed Au nanostar@Raman 
Reporter@silica sandwich nanoparticles, in which Raman molecules are sandwiched between an 
Au nanostar and a thin silica shell.43, 48 The silica coating can stabilize nanoparticles in aqueous 
solutions with high ionic strength and complex human fluids, leading to the improved stability of 
the device. 
In the current study, we developed a blood plasma separation unit (PSU) integrated paper 
based lateral flow strip (PLFS) for carcinoembryonic antigen (CEA) detection from whole 
human blood, which is an important tumor associated protein biomarker.49 In general, CEA 
circulates with elevated concentrations in the fluids of patients with malignancies, such as colon 
and rectal, ovary, breast, lung cancer and pancreas cancers.50 High apparent separation efficiency 
and separation yield of the PSU were achieved through the employment of three layers of blood 
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filtration membranes, which are designed specifically to separate plasma from whole blood 
samples. The membranes in the PSU were respectively functionalized with salt (sodium 
chloride), surfactant (TWEEN 20) and salt (sodium chloride). The first layer of membrane with 
salt functionalization was utilized to trapping RBCs in its fiber network; while the second layer 
with surfactant was used to accelerate the separated plasma to pass through the second layer. The 
third layer was also immobilized with salt, which was employed to ensure that the escaped RBCs 
can be trapped inside of the PSU. The three-layer construction guarantees that the PSU is capable 
of separating blood plasma with high efficiency and separation rate. During CEA detection, 
SERS nanoparticles (Au nanostar@Raman Reporter@silica sandwich nanoparticles) were 
utilized as signal reporters, which endows high sensitivity and strong anti-interference ability to 
the PSU-PLFS in whole blood samples. As a result, a LOD of 1 ng/mL of CEA was obtained, 
which was below the cut-off value that presents in the blood samples of cancer patients. 
Moreover, owing to the advantages of PLFS, the PSU-PLFS was capable of sensing CEA 
directly from human whole blood without any sample-pretreatment, which shows a great 
potential in the POC setting.  
 
3.2 REAGENT AND INSTRUMENTS 
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, Na3PO4·12H2O, 
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Bovine serum albumin (BSA), 
sodium chloride, streptavidin were purchased from Sigma-Aldrich and used without further 
purification. Sucrose was purchased from VWR. 4-Mercaptobenzoic acid (technical grade, 90%) 
(4-MBA) was purchased from Sigma-Aldrich. 3-Triethoxylsilylpropyl succinic anhydride 
(TEPSA) was obtained from Gelest Inc.  
Carcinoembryonic antigen and anti-CEA antibody were procured from Sigma-Aldrich. Glass 
fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards with Hi Flow 
plus cards (HF090MC100 with RK12312 Membrane (0.45 μm)), and nitrocellulose membrane 
(RK13464 (0.22 μm)) were purchased from Millipore (Billerica, MA). Whole human blood was 
purchased from Innovation Inc. 
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3.3 PREPARATION PROCEDURES 
3.3.1 Preparation of Nanoparticles 
 
Figure 3.1. TEM images of the Au nanostar@MBA@SiO2 sandwich nanoparticles a) low 
magnification and b) high magnification. 
 
Figure 3.2. FT-IR spectrum of the carboxyl-group labeled SERS NPs. The peak at 1702 cm-1 is 
assigned to the C=O stretching vibration in COOH of TEPSA. 
The Au nanostars, the SERS probes and the detection antibody labelled SERS probes were 
synthesized according to our previous paper.43 The preparation procedure is illustrated in Figure 
3.3. Briefly, the sandwich typed SERS probes were synthesized by adding 1.0 μM of 4-MBA 
into the Au nanostar suspension. Then 200 μL of 1% TEOS and 15 μL of ammonium solution 
were added into the mixture with 20 min intervals. After the SERS probes were formed, the 
resulting solutions were centrifuged and resolved in 500 μL of ethanoic solution. 100 μL of 
TEPSA was added to the SERS probe solution and then incubated overnight to achieve the 
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carboxyl-groupterminated SERS probes. The successful conjugation of carboxyl-group onto the 
surface of SERS NPs was confirmed by FT-IR spectra (Figure 3.1). The carboxyl-
groupterminated sandwich nanoparticles were then activated by adding a PBS buffer solution 
containing 50 mM NHS and 200 mM EDC and then incubated for 1 h. Subsequently, 100 μL of 
1.0 mg/mL detection antibody was added, and the mixture was incubated overnight. After that, 
the mixture was centrifuged and washed with a PBS buffer three times to remove excessive free 
antibody. The resulting SERS probe conjugates were stored in 100 μL of eluent buffer (20 nM of 
Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) solution for future use. 
The morphology and corresponding characterization can be found in our previous published 
papers.43 The successful conjugation of the detection antibody onto the SERS NPs was 
confirmed by the FT-IR spectrum (Figure 3.2). 
 
 
Figure 3.3. Schematic illustration for synthesis of detection antibody functionalized SERS 
probes. 
 
3.3.2 Functionalization of Blood Plasma Filtration Membranes 
A PSU contains three layers of blood filtration membranes (GR membrane). Each membrane 
was cut with a dimension of 5.5 mm × 3 mm. Two batches of membranes were respectively 
soaked and incubated in salt solution (0.154 M of sodium chloride) and surfactant solution 
(TWEEN 20 (20%)) for 1 h. Then the treated membranes were dried at room temperature for 2 h. 
The resulting membranes were stored in desiccators at room temperature for future use. During 
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PSU assembling, each layer of membrane has an overlap of 1.5 mm with each other (as shown in 
Figure 3.4).  
 
Figure 3.4. Schematic illustration of a PSU-PLFS.  
 
3.3.3 Preparation of Blood Plasma Separation Unit Modified Test Strip  
A PSU-PLFS contains PSU, conjugate pad, nitrocellulose (NC) membrane and absorption 
pad. The PSU contains three layers of blood filtration membranes, which were treated with salt, 
surfactant and salt respectively. Each layer of membrane was laminated on a plastic backing with 
an overlap of 1.5 mm. As shown in Figure 3.4, the top layer of membrane is modified with salt 
solution, while the second layer is modified with TWEEN 20. The third layer of membrane is 
also modified with salt solution, and it has an overlap of 2 mm with conjugate pad, which 
ensures that the solution could migrated through PSU to the PLFS. The optical image of the side 
view of a PSU is illustrated in Figure 3.5. Then the conjugate pad, NC membrane and absorption 
pad were assembled following the general fabrication procedure of a PLFS. In brief, the test line 
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and control line on the NC membrane (Hi Flow plus cards HF090MC100 with RK12312 
Membrane (0.45 μm)) were prepared by dispensing the solutions of capture antibody and 
secondary antibody respectively with a home-made dispenser. The distance between the test and 
control lines was 3 mm. The membrane was then dried at 37°C for 1 h and stored at 4°C in a dry 
state. Finally, the PSU, conjugate pad, NC membrane, and absorption pad were assembled on a 
plastic adhesive backing (60 mm × 30 cm) (HF000MC100). Each part overlapped 2 mm to 
ensure that the solution could migrate through the entire test strip during the assay. Test strips 
with a 3-mm width were cut using a paper cutter. After a PSU-PLFS was assembled, the solution 
of detection antibody labelled SERS probes were loaded on the conjugate pad prior to the test.  
 
Figure 3.5. Optical image of the side view of a PSU, which contains membrane layer-1, layer-2, 
layer-3 and conjugate pad.  
3.4 PERFORMANCES 
3.4.1 Operation Principle  
 A PSU-PLFS was comprised of a blood plasma separation unit and a conventional lateral 
flow test strip. The PSU was utilized to intercept RBCs inside of the unit, while the PLFS was in 
charge of detecting biomarkers from the separated plasma from the PSU. As shown in Figure 
3.4, the PSU contains three layers of blood plasma filtration membranes, which are placed 
successively in the front edge of a PLFS. During a typical assay, 30 μL of blood sample solution 
containing different concentrations of target antigen was loaded at the first filter layer of the 
PSU, which was modified with salt. The salt immobilization induced the aggregation of RBCs 
inside of the fiber network of the membrane; while the separated plasma containing target 
biomolecules kept migrating along the PSU and then reached the second filter layer. The second 
layer of filter membrane was immobilized with TWEEN 20, which expedited the separated 
solution moving forward to the third filter layer. The third filter layer of PSU was also 
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functionalized with salt, which guaranteed that the escaped RBCs from the first two filter layers 
can still be captured inside of the PSU, realizing efficient separation of plasma from whole blood 
samples.  After that, 100 μL of buffer was added onto the second layer of filter. Owing to 
capillary force, the separated plasma containing target antigen with running buffer migrated from 
PSU to the conjugate pad of the PLFS, where the reaction between target antigens with antibody 
linked SERS probes occurred. Then the resulted complexes kept moving along with the test strip 
until they reached the test line and captured by capture antibody through the formation of a 
sandwich structure (capture antibody-antigen-detection antibody/SERS). The rest of 
SERS/detection antibody conjugates migrated over the test line and captured by the control line 
where the secondary antibody was immobilized. During data acquiring, the test strips were 
analyzed by a portable i-Raman reader.  The Raman peak intensity was in proportion to the 
concentration of target antigen, which was used for quantitative work.  
3.4.2 Apparent Separation Efficiency and Yield  
Separation efficiency and separation yield are the two most critical factors in judging the 
performances of a blood plasma separation device. In the current study, we utilized the concepts 
of apparent separation efficiency (ASE) and apparent separation yield (ASY) to evaluate PSU 
performances for separating RBCs from human blood sample. The processing steps of the ASE 
of a PSU was illustrated in Figure 3.6. In Step 1, 30 μL of human blood sample was firstly 
loaded on the first layer of filtration membrane on a PSU. After the blood plasma separation was 
accomplished, a scanner was used to capture the optical images of PSUs. In Step 2, the captured 
images were converted to grayscale models through the Photoshop software.  In Step 3, the 
images from Step 2 were inverted from black-white model to white-black model.  During 
analysis, the grayscale intensity per unit area of the images in Step 3 were measured and 
processed using the ImageJ software. Experimental factors, including layers of the blood 
filtration membranes and the chemical functionalization of the membranes were optimized 
according to the ASE of a PSU. Since a PSU contains three layers of membrane, therefore, we 
utilized ASE21 and ASE31 to respectively demonstrate the ASEs between layer 1 and layer 2, and 
the ASE between layer 1 and layer 3.  The ASE21 and ASE31 were calculated according to 
Equation (1) and (2) below: 
                                                      ASE21=(Ilayer1-Ilayer2)/Ilayer1                                                                        (1) 
                                                      ASE31=(Ilayer1-Ilayer3)/Ilayer1                                                                        (2) 
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Figure 3.6. Optimizations and processing steps of ASE of a PSU when human blood sample was 
loaded. Each blood plasma separation test was repeated three times under the same condition. 
 
Where I represents the intensity of the grayscale in Steps 3 divided by the area of the blood 
filtration membrane. The PSU was fabricated on the substrates of blood filtration membranes. 
This kind of membrane was designed specifically for blood filtration through capturing RBCs in 
the larger pores, while the plasma flows down into the smaller pores on the downstream side of 
the membrane. Therefore, the optimizations of the filter membranes are crucial for improving the 
ASE and ASY. Under the same experiment conditions, compared with one layer (Figure 3.7a), 
three layers of salt treated membranes (Figure 3.7c) exhibited dramatically enhanced ASE21 
from 16.1% to 91.6%, which proved that multiple layers are crucial for elevating the PSU 
performances. Same conclusion can be drawn when the optical images of PSUs in Figure 3.6a 
and Figure 3.6c were analyzed. Most of the RBCs can be captured and retained inside of the first 
membrane layer of the three-layer membrane PSU. On the contrary, only small amount of RBCs 
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can be retained at the front edge of the one-layer membrane PSU. The rest RBCs kept migrating 
along on the membrane surface, which significantly contaminated the unit, leading to poor ASE. 
The membrane layers from 2 to 5 were also studied through analyzing ASE12 of the PSUs. It can 
be clearly seen that the ASE12 increases as the layer of membrane increases (Figure 3.8a). 
Considering the ASE12 performances and cost, 3 layers of filtration membranes was chosen as 
the optimal layer amount. 
 
Figure 3.7. ASE12 and ASE23 of a PSU with different functionalization when human blood 
sample was loaded. 
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Figure 3.8. Experimental optimizations of the PSU. The effect of a) different layers of blood 
filtration membranes; b) NaCl concentrations; c) TWEEN 20 amount on ASE12 and ASE13. 
 
Chemical treatment is another important factor to improve ASE, especially salt treatment. 
This is because that RBCs contain a weak negative charge, which contributes to stabilizing RBC 
suspension in plasma. While salts can destabilize RBC suspension through generating osmotic 
pressure across the RBC membrane. In addition, salt addition can suppress the electric double 
layer on the RBC surfaces, which results in the shape change and close packing of RBCs, leading 
to the aggregation of RBCs. Blood filtration membranes were optimized through employing 
different concentrations of NaCl solutions to achieve high ASE. As descripted in Figure 3.8b, 
with the increase of NaCl concentration, the ASE12 and ASE13 increase respectively. This is 
because that with the increase of salt concentration, the degree of aggregation increases, which 
contributes to elevated ASE. From the figure we can observe that 0.15 M of NaCl is the optimal 
salt concentration, which maintained the ASE above 90%. However, owing to the formation of 
the RBC aggregation in the present of salt, the generated RBC lumps might block the membrane 
and slow down the rate of plasma separation. Based on this reason, surfactant was introduced to 
functionalize the second layer of filter membrane for accelerating the separation progress. From 
the study we found that with the increase of TWEEN 20 amount, the separation rate improved 
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accordingly. Although the ASE decreased to some extent, the ASE13 of the PSU was still kept 
above 90% (Figure 3.8c).  The influence of surfactant was further studied through immobilizing 
the entire PSU with TWEEN 20. From Figure 3.6d we can clearly see that a large amount of 
RBCs migrated from layer 1 to layer 2, which indicated severely decreasing in the ASE12 and 
ASE13 of a PSU (Figure 3.7d). This result showed that excessive amount of surfactant can 
significant decrease the ASE even under the condition of salt functionalization. As a result, 20% 
of TWEEN 20 was the chosen as the optimal amount.  
Separation yield describes the percentage of extracted plasma volume from the total volume 
of blood injected. In the current study, we introduced the concept of ASY for judging the PSU 
performances. The ASY was calculated according to Equation (3) below: 
 ASY=1-(weight of RBCs absorbed on membrane (g)/weight of 30 μL of blood sample (g))   (3)  
The weight of RBCs absorbed on membrane was calculated according to the weight 
difference of membrane layer-1 before and after blood plasma separation. Figure 3.8 describes 
the ASYs of six PSUs when 30 μL of human blood sample is loaded on each PSU. From the 
figure we can see that the ASYs of PSUs approximated 30%, which indicated that the PSU was 
capable of separating plasma from blood samples with outstanding efficiency and stability, 
following the following PLFS tests with dramatically reduced interference from RBCs. 
 
Figure 3.8. ASY of PSUs when 30 μL of human blood sample was loaded. The test of blood 
plasma separation was repeated six times on six PSUs. 
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3.4.3 Analytical Characterization in Whole Human Blood 
In order to evaluate the performances of the PSU-PLFS, whole blood sample solutions 
containing different concentrations of CEA (ranging from 0 to 100 ng/mL) were measured under 
optimal experimental conditions. During a typical test, 30 μL of blood sample was loaded on the 
first filter layer of the PSU. After blood plasma separation, RBCs were captured inside of the 
PSU, whereas plasma containing target CEA was wicked by capillary force into the PLFS, which 
was functionalized with detection and capture reagents for CEA measurement. In order to 
improve detection sensitivity, 100 μL of PBS running buffer was then dropped onto the second 
filter layer of the PSU, which was used to drive the rest CEA molecules to migrate to the 
detection zone on the PLFS. In addition, buffer introduction can also reduce non-specific 
absorption on the detection area. As descripted in Figure 3.9a, the test line intensity increases 
with the increasing of CEA concentration in blood samples. Moreover, most of the RBCs are 
intercepted inside of the PSU; while the detection area of the PLFSs are not contaminated by 
RBCs. This result indicates that the PSU-PLFS is capable of directly sensing target biomolecules 
from whole blood samples. Figure 3.9b and c respectively exhibits the SERS spectra obtained 
from the PLFS and the corresponding calibration curve. The regression equation was y = 1158.5x 
– 239.0 with a correlation coefficient of 0.98. The detection limit of target CEA was found to be 
1 ng/mL, which was estimated based on three times of signal-to-noise ratio. A linear detection 
range from 5 ng/mL to 100 ng/mL was obtained and was suitable for quantitative work. The 
above results implied that the developed PSU-PLFSs were working sensitively and reliably, 
which attributes both to the high separation efficiency of the PSU and also to the high stability 
and sensitivity of the sandwich-typed SERS probes in the complex human fluids.   
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Figure 3.9. Optical images (a), SERS spectra (b) and the corresponding calibration curve of the 
PSU-PLFSs for CEA detection in whole blood samples. 
 
3. 5. CONCLUSION 
A PSU has been developed for separating blood plasma from whole blood samples with high 
separation efficiency and separation yield. The outstanding performance of the PSU was 
achieved through employing NaCl and TWEEN 20 functionalizations on blood filtration 
membranes. The treatment of the NaCl solution to first and third filter layers guaranteed that the 
RBCs can be firmly intercepted inside of the PSU; while the TWEEN 20 treatment helped 
accelerate separating plasma from the sticky whole blood sample. The PSU was then integrated 
into a PLFS for cancer protein biomarker detection. A LOD of 1 ng/mL of CEA was obtained by 
the PSU-PLFS from whole blood samples. The high sensitivity was attributed to the reduced 
interferences from whole blood and the improved stability of the SERS probe in human fluids. 
Moreover, the fabricated PSU can be employed in various paper devices to reduce the RBCs 
interferences, showing great potential in the POC settings in remote and developing regions.   
 
48 
 
Chapter 4: PLASMONIC CHIP-TEST STRIP IN WHOLE BLOOD 
TESTING 
4.1 NANOSTRUCTURED CHIP INTEGRATED TEST STRI P 
The demands of point-of-care testing (POCT) have steadily risen during the past half century. 
The global cost of POCTs was valued at USD 17.6 billion in 2018 and is expected to reach a 
value of 36.2 billion by the end of 2025.  The features of an ideal POC device are aimed at 
delivering user-friendly, cost-effective and robust care near patient’s home.51 Among POC 
devices, capillary flow devices are the most widely distributed and employed forms.52 The two 
representative examples are pregnancy test strips and glucose test strips. The prevalence is owing 
to that they are portable and user friendly, which is suitable for timely self-testing without any 
professional training. Moreover, the components of test strips are made from papers, which are 
low-cost and facilely storable, enabling multiple-time screenings over a specific period. The 
underlying mechanism of a test strip is mainly based on sensing of a target molecule or a 
biomarker. For example, a pregnancy test strip is manufactured for detecting human chorionic 
gonadotrophin (hCG) in urine samples. If the hCG level attains the detectable limit of a pregnant 
test strip, the optical signal from the captured bioprobe linked Gold nanoparticles (GNPs) can be 
observed and used for signal readout. However, as a POC tool, there are tradeoffs. In order to 
simplifying test procedures and accelerating sample screening, sensitivity and accuracy of a test 
strip are sacrificed. As a result, most of the current test strips cannot be applied for early-stage 
biomarker sensing, owing to that early-stage diseases always relate with trace-amount of 
biomarkers. Therefore, it is of great significant to develop POC tools with enhanced 
performances to address the unmet need for sensitive and reliable measurement of early-stage 
biomarker, which is beneficial to providing timely diagnosis and properly management and 
finally increasing patient survival rates.  
Optical and electrochemical techniques have been widely employed in test strips. Sensing 
signals are generated through interfacing biological recognition events in test strips and then 
transmitted through transducers to a signal processor for data analysis. Integrating nanomaterials 
into test strips is an effective way to improve detection sensitivity.52c It is because these 
nanomaterials possess unique properties, such as inherent large surface area, excellent 
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biocompatibility, outstanding conductivity and catalytic ability, which help amplify the 
transduction of biorecognition events, retain bioactivity of biomolecules and accelerate signal 
transduction, leading to an elevation in detection sensitivity. GNP is the most representative 
signal tag that used in test strips, owing to the fact that GNPs are stable, easy to synthesize and 
can provide strong contrast with the white background of a test strip. Moreover, the optical 
properties of GNPs can be easily tuned through changing their size and morphologies, which 
helps amplify response signal. Besides GNPs, silver nanoparticles,53 magnetic nanoparticles,54 
fluorescent based quantum dots and organic dyes and fluorescent nanoparticles55 have also been 
employed as signal reporters to elevate the performances of test strips. However, most of the 
above mentioned sensors fail in real-world sample applications due to non-specific interferences 
and strong color interference from sample matrices, especially from whole blood samples. In 
order to overcome this issue, sample pre-treatment, sample dilutions and introducing signal 
amplification techniques are always required. As a result, the involved complicate experimental 
procedures limit their applications in POC uses.  
Surface-enhanced Raman scattering (SERS) is a powerful technique that possesses ultra-
sensitivity by amplifying the Raman scattering signal by orders of magnitude if a molecule is 
associated to the surface of a rough metal or plasmonic nanomaterial.56 This improvement is 
based on the coupling of EM field enhancement of nearby noble metal nanomaterials, which 
leads to the formation of “hot spots” for SERS enhancement. The tremendous enhanced Raman 
responses make SERS technique attractive for ultrasensitive sensing.57 In addition, SERS 
technique owns “fingerprint” feature to elevating the anti-interference resistance to nonspecific 
molecule, which is well-suited for specifically targeting biomolecules from complex sample 
matrices. Gold and silver are the most representative SERS-active nanomaterials. They can be 
integrated into sensors as nanoparticles, patterned nanostructures or sharp metal tips. In order to 
maximize the effect of enhancement, the size and morphology of SERS-active nanomaterials 
have been precisely controlled. Recently, our group developed a three-dimensional (3D) 
plasmonic nano-architecture immunosensor for cancer biomarker sensing.40 A 3D confined 
plamonic field was created by coupling the gold triangle nanoarray with the sandwich-typed 
SERS probe, which generated a high density of “hot spot” for ultrasensitive detection. In 
addition, the gold triangle nanoarray chip can concentrate the plasmonic field and create hot 
spots near the sharp tips, leading to dramatically improvement in SERS signal and detection 
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sensitivity. As a result, this immunosensor was capable of detecting cancer protein biomarker 
directly in clinical blood plasma samples. Although the immunosensor exhibited advantages of 
shorter detection time compared with the standard ELISA method, it is difficult to be utilized as 
a POC tool, since expert personnel is still required to operate the test. 
In the current study, we designed a 3D plasmonic nano-architecture functionalized lateral 
flow test strip, which can sustain the property of a POC tool, at the same time, realize 
ultrasensitive measurement of biomolecules in complex human fluids. Similar with the above 
mentioned gold triangle nanoarray chip, the proposed gold nanopyramid array chip in this study 
also presents sharp tips, which is expected to provide high sensitivity for SERS sensing. During 
the device fabrication, the capture antibody was immobilized on the chip surface; while the 
SERS gold nanostar@Raman molecules@silica sandwich nanoparticles were labeled with 
detection antibody. In the present of target molecule, the detection antibody linked SERS 
nanoparticles are captured over the gold pyramid nanoarray, forming a confined 3D plasmonic 
field, leading to the significantly enhanced electromagnetic field in intensity and in 3D space. 
During the detection, no extra washing operations were required owing to the present of a 
surfactant bridge proposed in this study. The surfactant bridge was built across the chip surface 
to reduce the surface tension, which ensures the sample fluid can flow smoothly across the entire 
device. Compared with the signal from SERS nanoparticles on NC membrane, the SERR signal 
from the 3D plasmonic nano-architecture was improved significantly. As a result, the developed 
plasmonic chip integrated test strip was capable of detecting TBI protein biomarker directly from 
the plasma samples of clinical patients, showing great promises for detection of biomarkers in 
POC applications. 
4.2 MATERIALS AND METHODS  
4.2.1 Reagents and Materials 
4-Mercaptobenzoic acid (technical grade, 90%) (4-MBA) was purchased from Sigma-Aldrich. 
3-Triethoxylsilylpropyl succinic anhydride (TEPSA) was obtained from Gelest Inc. 
Nhydroxysuccinimide (NHS), 1-ethyl-3-(3-(dimethylamino)-propyl) carbodiimide (EDC), 11-
mercaptoundecanoic acid (MUA), 11-mercapto-1-undecanol ethanolic (MU) and tetraethyl 
orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, sucrose, Na3PO4·12H2O, 
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Na3PO4·12H2O, BSA (bovine serum 
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albumin) and sodium chloride were purchased from Sigma-Aldrich and used without further 
purification. Sucrose was purchased from VWR. S-100β and anti-S-100β antibody were 
procured from Sigma-Aldrich. S-100β ELISA Kits were purchased from R&D System. The 
blood plasma was purchased from US Biological Life Science (P4252-56 Plasma, Human, IgG 
Free). Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards 
with Hi Flow plus cards (HF090MC100 with RK12312 Membrane (0.45 μm)), and nitrocellulose 
membrane (RK13464 (0.22 μm)) were purchased from Millipore (Billerica, MA). Quartz slides 
were purchased from Fisher Scientific Inc. Polystyrene (PS) beads (500nm diameter) were 
purchased from Thermo Scientific. Clinical blood plasma samples were collected from TBI 
patients and provided by WVU medical school.  
4.2.2 Instruments and Characterization 
All Raman spectra were acquired with a portable B&W Tek i-Raman Plus. Fourier transform 
infrared (FT-IR) spectra were obtained under the attenuated total reflection (ATR) mode with 
Thermo Nicolet 6700 spectrometer. The nanoparticles were characterized with a transmission 
electron microscope (TEM, JEOL JEM-2100F) at an acceleration voltage of 200 kV. UV−visible 
absorption spectra were obtained with a Shimadzu UV-2550 spectrometer. Titanium and gold 
metals were deposited by e-beam evaporator (Kurt J Lesker). A scanning electron microscope 
(JEOL-JSM-7600F) was used to image the gold nanopyramid array. Optical characterization of 
gold nanopyramid array was done using an Ocean Optics 4000 spectrometer and DT-MINI-2-
GS. 
4.3 PREPARATION PROCEDURES  
4.3.1 Synthesis of Gold Nanopyramid Array Chip and Functionalization of Capture Antibody on 
Chip 
Nanosphere lithography fabrication technique was used to fabricate the nanopyramid 
structure. Initially quartz slides were cut in the form of chips with dimensions around 1cm x 
1cm. The chips were cleaned in acetone, methanol and DI water for 5 min in each respectively. 
The cleaned quartz chips were immersed in acid piranha at 90 °C for 1 h, which makes the quartz 
surface hydrophilic. Further, the chips were rinsed in DI water and 500nm diameter polystyrene 
(PS) beads were dip-coated to form a Hexagonally Closed Pack (HCP) monolayer. The 
monolayer is allowed to dry for 10min. Later, a 5 nm titanium film was deposited followed by 
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250 nm gold film using e-beam evaporator. The metal deposits on to the quartz through the 
interstitials spaces of nanospheres to form pyramid shape. The polystyrene beads were removed 
by ultrasonication of chips in methanol, leaving the gold nanopyramids on the quartz substrate. 
Due to the titanium adhesive layer, the gold nanopyramids were intact on the quartz substrate.  
The fabricated chip was cleaned by successive immersion in ethanol and D.I. water for 10 
min, respectively. The cleaned gold films were incubated overnight in a solution containing 100 
mM MUA/100 mM MU and then washed using ethanol and D.I. water, respectively. The 
successful conjugation of MUA/MU onto the gold film was confirmed by FT-IR spectra (Figure 
4.1). The resulting MUA/MU modified chip was activated by immersion in a solution containing 
50 mM NHS/200 mM EDC in a PBS solution. The chip was incubated overnight in a PBS 
solution containing 1 mg/mL of anti-S-100β. Successful conjugation of capture antibody onto the 
chip was confirmed by FT-IR spectra (Figure 4.2), in which the peak at 1541 cm-1 indicated the 
N–H bending. After immobilization of the antibody, the chip was successively rinsed with D.I. 
water and PBS solution to remove free and excess antibody molecules.  
 
 
Figure 4.1. FT-IR spectra of MU/MUA functionalized chip. The peak at 1705 cm-1 peak is 
assigned to the C=O stretching vibration. 
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Figure 4.2. FT-IR spectra of the capture antibody functionalized chip. The peak at 1541 cm-1 
corresponds to the N-H bending in the antibody. 
4.3.2 Functionalization of Surfactant Bridge on Chip Surface  
The surfactant bridge contains two components: TWEEN 20 and glucose. 1 μL of TWEEN 20 
was dropped on and then spread evenly on the surface of the capture antibody immobilized 
plasmonic chip. After that 0.01 g of glucose was sprinkled on the TWEEN 20 covered chip 
surface. The surfactant bridge functionalized chip was stored in dry ambient for 0.5 h and then 
stored at 4°C for further use.  
4.3.3 Synthesis of Nanoparticles and Conjugation with Detection Antibodies.  
The Au nanostars, the SERS probes, and the nanoparticles conjugated with detection 
antibodies were synthesized according to our previous paper.58 Briefly, the Au nanostar@Raman 
molecule@Silica sandwich SERS probes were synthesized by adding 1.0 μM Raman molecules 
into the Au nanostar suspension. Then, 200 μL of 1% TEOS and 15 μL of ammonium solution 
were added into the mixture, successively. After the SERS probes were formed, the resulting 
solutions were centrifuged and resolved in 500 μL of ethanoic solution. The Au nanostars were 
coated with a 2−3 nm thick silica layer on the outer surface. Next, 100 μL of TEPSA was added 
to the SERS probe solution and then incubated overnight to achieve the carboxyl-group 
terminated SERS probes. The conjugation of carboxyl-group onto the surface of SERS 
nanoparticles was confirmed by FT-IR spectra (Figure 4.3). The carboxyl-group terminated 
54 
 
sandwich nanoparticles were then activated by adding a PBS buffer solution containing 50 mM 
NHS and 200 mM EDC and then incubated for 1 h. Subsequently, 100 μL of 1.0 mg/mL 
detection antibody was added, and the mixture was incubated overnight. The successful 
conjugation of detection antibody onto SERS nanoparticles was confirmed by the FT-IR spectra 
(Figure 4.4). After that, the mixture was centrifuged and washed with a PBS buffer three times 
to remove excessive free antibody. The resulting SERS probe conjugates were stored in 100 μL 
of eluent buffer (20 nM of Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% 
sucrose) solution for future use. The corresponding characterizations can be found from Chapter 
2 in this dissertation. 
 
Figure 4.3. FT-IR spectra of the carboxyl-group modified SERS probe. The peak at 1709 cm-1 
peak is assigned to the C=O stretching vibration in COOH of TEPSA. 
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Figure 4.4. FT-IR spectra of the detection antibody functionalized SERS probe. The peaks at 
1666 and 1550 cm-1: correspond to the N-H bending in the antibody. 
 
4.3.4 Preparation of Chip-Test Strip 
 
Figure 4.5. Schematic illustration of the operation principle of chip integrated PLFS.  
 
Figure 4.5 shows the schematic diagram of the fabricated chip-PLFS, which consists of five 
components: a sample pad, a conjugate pad, two nitrocellulose membranes (NC membrane), a 
gold nanopyramid array chip and an absorption (or wick) pad. All the components were mounted 
on a common backing layer (typically an inert plastic, e.g., polyester). The sample pad was 
saturated with a Tris-HCl buffer (pH 8.0) containing 0.23% Triton X-100 and 0.05 and 0.15 M 
NaCl. The pad was then dried at 37 °C for 2 h and stored in a desiccator at room temperature 
(RT). Then, the surfactant bridge covered capture antibody labeled chip was placed between two 
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NC membranes. The dimension of each NC membranes was 1.1 cm × 0.3 cm. The detection 
antibodies modified SERS probes were dropped onto the conjugate pad. Finally, all the five 
processed components were assembled onto a plastic adhesive backing layer. The paper 
components were overlapped with 2 mm to ensure that the solution was able to flow through the 
whole strip. Each paper component was cut to be 3 mm wide by a paper cutter (Swingline 12 in. 
ClassicCut Lite Trimmer). Before testing, 5 μL of detection antibody linked SERS probes was 
loaded onto the conjugate pad. During testing, 100 μL of sample solution containing a certain 
concentration of target biomolecule was dropped on the sample pad. 
4.4 RESULTS AND DISCUSSION  
4.4.1 Characterizations of Gold Pyramid Nanoarray  
 
Figure 4.6. a) TEM images of the gold nanostar@MBA@SiO2 sandwich nanoparticles; SEM 
images of b) large-area view and c) enlarged view of the gold nanopyramid array, and d) UV-Vis 
reflection spectra of the gold nanopyramid array.  
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The synthesized SERS nanoparticles contain a core of gold nanostar and a silica shell; while 
the Raman molecules are sandwiched between the gold core and the silica shell. The metal core 
is able to amplify the SERS signal; while the silica shell can protect the nanoparticles away from 
the interferences of surrounding environment. In addition, numerous of Raman molecules can be 
concentrated inside of the silica shell of one single SERS probe, which can significantly improve 
sensitivity. Figure 4.6a, exhibits the TEM image of the gold nanostar@MBA@SiO2 sandwich 
nanoparticles. It can be clearly seen that the gold nanostars exhibit a star shape and possess sharp 
tips, which contributes to remarkable signal amplification. A 4~5 nm thick SiO2 layer can also be 
observed from the TEM image, which indicates that the silica shell was successfully coated onto 
the nanoparticles. Figure 4.6b and c show the SEM images of the gold nanopyramid arrays. The 
gap between the adjacent pyramid corners in the gold pyramid nanoarray was about 40 nm, 
which enables the coupling of LSPR. The UV-Vis reflection spectra from Figure 4.6d further 
confirms that the gold nanopyramid array is capable of coupling LSPR, generating a high density 
of hot spots for the SERS enhancement.  
4.4.2 Operation Principle  
The prepared plasmonic chip-PLFS contains dry reagents which can be activated by applying 
a fluid sample (Figure 4.5). Once the sample solution is dropped onto the sample pad of the 
chip-PLFS, it will flow automatically from sample pad to conjugate pad by capillary force. On 
conjugate pad, an interaction between target protein and detection antibody linked SERS probes 
occurs. The resulting complex continues to move along with the chip-PLFS until it reaches the 
boundary between the NC membrane and the plasmonic chip. With the help of surfactant bridge, 
the sample solution can migrate smoothly across the chip surface. At the same time, the 
surfactant bridge starts to dissolve and the capture antibody labeled chip surface is exposed for 
capturing the above obtained bio-complex. Figure 4.7 shows that the surfactant bridge is 
dissolved 2 min after running buffer is added, indicating that the fluid flows smoothly across the 
device, meanwhile the surfactant bridge doesn’t block signal acquisition from chip surface.   
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Figure 4.7. Optical images of a chip-PLFS before and after the sample solution is loaded. 
As a result, a sandwich-typed structure of SERS probe/detection antibody-protein-capture 
antibody is formed on the plasmonic surface, leading to the formation of a confined 3D 
plasmonic field for generating ultrasensitive SERS signal. The operation principle is illustrated 
in Figure 4.8. A portable Raman spectrometer is employed to record the SERS signal from the 
plasmonic chip surface. Under excitation by a 785 nm laser, the SERS signal is generated from 
the MBA (Raman reporter) molecules inside of the captured SERS probes. The obtained SERS 
signal is in proportion to the concentration of target protein, which is used for quantitative work.   
 
Figure 4.8. Schematic illustration of the reactions on chip integrated PLFS.  
 
4.4.3 Comparison of Raman Signal on Different Substrate 
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Figure 4.9. Comparison of SERS signal on Au pyramid, planar Au chip and NC membrane 
respectively. 
 
In order to verify the substantial improvement in SERS signal, a comparison study was 
conducted. Three configurations of plasmonic hierarchical architecture were employed as SERS 
substrates, including SERS NPs on Au nanopyramid array chip, SERS NPs on planar Au chip 
and SERS NPs on NC membrane. From Figure 4.9 we can find that the SERS NPs/Au 
nanopyramid array chip exhibits the highest SERS signal at the specific Raman peak of 1084 cm-
1, while the signal from SERS NPs/NC membrane is much less efficient. This signal 
improvement is endowed from the high density of hot spots in the 3D hierarchical architecture of 
the SERS NPs/Au nanopyramid array chip. In addition, both of gold nanostars are gold 
nanopyramid array possess LSPR bands at ~785 nm, which are overlapped with the wavelength 
of excitation laser, leading to dramatically improvement in sensing performance. This result also 
allows us to investigate the effects of the plasmonic chip (Au planar chip and Au nanopyramid 
array chip) and the non-plasmonic substrate (NC membrane) on the performance of the SERS-
PLFS.  
 
4.4.4 Optimizations  
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Figure 4.10. Optimization of the experiment conditions for chip-PLFS. a) Effect of the chip 
displaying position on the S/N ratio of chip-PLFSs, b) effect of SERS probe volume on the S/N 
ratio, c) effect of effect of the amount of capture antibody modified on chip on the S/N ratio. 
In order to elevate the performance of the chip-PLFS, human IgG and anti-IgG antibody was 
chosen as models to optimize the device. 10 ng/mL of human IgG was used as target molecules 
in all of the following optimization experiments. The incubation time of detection antibody with 
target antigen, and capture antibody with target antigen significantly influences the binding 
efficiency, as well as the sensitivity. Therefore, the binding timing and extent need to adjusted, 
which can be implemented through optimizing the displaying positions of plasmonic chip in test 
strip. The displaying chip position means the distance between the front boundary sides of the 
plasmonic chip with the conjugate pad. Figure 4.10a reveals that the S/N ratio of the SERS peak 
increased with the growing distance of the plasmonic chip away from the conjugate pad until the 
distance reached 11 mm, which means when the distance is below of 11 mm, the binding time 
between detection antibody and antigen is not enough. Further increasing the distance led to a 
decrease in the binding time between the detection antibody/antigen complexes with the capture 
antibody, since most of the biomolecules were immediately adsorbed by the wicking pad after 
they arrived at the chip surface. As a result, the optimal displaying distance of the chip in test 
was 11 mm away from the conjugate pad. Another two important parameters which affect the 
capturing ability of signal reporters are the amount of nanoparticle linked detection antibody and 
the concentration of capture antibody on the chip surface. From the S/N ratios (Figure 4.10b and 
c), the optimal concentration of SERS probe was 5 μL; while 1.5 mg/mL of capture antibody was 
the best amount.   
4.4.5 Measurement of S-100β in Buffer 
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Figure 4.11. SERS spectra (a) and calibration curve (b) of chip-PLFSs with MBA as Raman 
reporter for detection of s-100 β in PBS buffer.  
 
In order to evaluate the performances of the chip-PLFS, buffer solutions containing different 
concentrations of s-100β (ranging from 0 ng/mL to 100 ng/mL) were measured under optimal 
experimental conditions. During a typical test, 100 μL of sample solution was loaded on the 
sample pad of the chip-PLFS. After 30 min reaction, the SERS signal of the chip-PLFS was 
recorded by a portable Raman spectrometry. Figure 4.11a and b respectively exhibits the SERS 
spectra obtained from the plasmonic chip and the corresponding calibration curve. The 
calibration curve was obtained by plotting the SERS peak intensity at 1084 cm−1 from MBA as a 
function of the logarithmic concentration of s-100β. The regression equation was y = 184.3x + 
570.5 with a correlation coefficient of 0.93. The detection limit of this device for s-100β in 
running buffer was found to be 1 pg/mL, which was estimated based on three times of signal-to-
noise ratio. Compared with the results from the previously reported SERS-test strips, the 
proposed chip-PLFSs exhibited a 20 times improvement in detection sensitivity, which is 
endowed from the high density of hot spots in the 3D hierarchical architecture. In addition, both 
gold nanostars are gold nanopyramid array possess LSPR bands at ~785 nm, which are 
overlapped with the wavelength of excitation laser, leading to dramatically improvement in 
sensing performance. A linear detection range from 10 pg/mL to 100 ng/mL was obtained and 
was suitable for quantitative work.  
4.4.6 Measurement of s-100β in Clinical Blood Plasma Samples  
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The above results indicated that the developed chip-PLFSs were working sensitively and 
properly. In order to further verify the accuracy of the device, chip-PLFSs were employed to 
examine the s-100β level from plasma samples taken from six TBI patients. Commercial 
standard ELISA Kit was used as a comparison. Before testing clinical samples, the chip-PLFSs 
were calibrated with known concentrations of s-100β, which was spiked into 80% of commercial 
blood plasma respectively (P4252-56 Plasma, Human, IgG Free). The baseline concentration of 
s-100β in blood plasma matrices was estimated by an s-100β ELISA kit. No obvious signal can 
be observed from the blood plasma sample, which indicates that the baseline concentration of s-
100β in blood plasma is below the detection limit of the ELISA kit, showing no interference on 
s-100β sensing.  
 
Figure 4.12. SERS spectra (a) and calibration curve (b) of chip-PLFSs for detection of s-100 β in 
80% of blood plasma.  
 
Figure 4.12 shows the SERS spectra of the 3D hierarchical architecture integrated test strips 
in the presence of various concentrations of s-100 β in 80% blood plasma. From the SERS 
spectra we can see that the intensity of the SERS peak at 1084 cm−1 gradually increased with an 
increase in the s-100 β concentration. The SERS peak intensity (y) versus the s-100 β 
concentration (x) was fitted as y = 175.1x + 437.3 with the relative coefficient (R2) of 0.96, 
showing a linear detection range from 0.1 to 100 ng/mL, achieving a LOD of 5 pg/mL. The 
calibration curve indicated that the developed chip-PLFSs can work for s-100 β detection in 
blood plasma. After calibration, the developed chip-PLFSs were employed for detection of s-100 
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β from clinical samples of patients with TBI. The clinical samples were also examined by the 
standard ELISA method. Figure 4.13 exhibits the result comparison from the chip-PLFSs and 
the ELISA kit. The results showed that the results from chip-PLFSs were comparable from the 
ones from ELISA kits, suggesting that the proposed chip-PLFSs were capable of sensing s-100 β 
in clinical samples. Moreover, compared with ELISA kit, the proposed chip-PLFSs provide 
significant advantages, in terms of shorter sensing time (30 min vs several hours), simplified test 
procedures and inexpensive test.  
 
Figure 4.13. S-100 β concentrations in clinical blood plasma samples, which were measured by 
ELISA and the chip-PLFS, respectively.  
 
4.4.7 Measurement of s-100β in Whole Blood Samples  
In Chapter 3, we successfully detected target protein from whole blood samples by 
employing a PSU integrated paper test strip. In the current study, in order to further verify the 
performances of the chip-PLFSs, we challenged to test s-100β from whole blood samples 
through modifying a PSU into the developed chip-PLFS. During a typical assay, 30 μL of blood 
sample solution containing different concentrations of s-100β (ranging from 0 to 100 ng/mL) 
was loaded on the first filter layer of the PSU. After blood plasma separation, RBCs were 
blocked inside of the PSU, while the separated plasma containing target s-100β was wicked into 
the chip-PLFS, which was functionalized with capture and detection reagents for s-100β 
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measurement. 100 μL of PBS running buffer was then dropped onto the second filter layer of the 
PSU, which was used to drive the rest s-100β molecules to migrate to the detection zone on the 
chip-PLFS; meanwhile, buffer introduction can also reduce non-specific absorption on the 
detection area. As descripted by the SERS spectra in Figure 4.14a, the intensity of the typical 
Raman peak at 1080 cm-1 increases with the increasing of s-100β concentration in blood 
samples, which indicates that the PSU integrated chip-PLFSs are working properly in whole 
blood samples. Figure 4.14b shows the corresponding calibration curve. The regression equation 
was y = 20.7x + 578.9 with a correlation coefficient of 0.95. The detection limit of this device 
for target s-100β was found to be 50 pg/mL, which was estimated based on three times of signal-
to-noise ratio. A linear detection range from 0.1 ng/mL to 100 ng/mL was obtained and was 
suitable for quantitative work. The above results implied that the developed PSU-chip-PLFSs 
were working sensitively and reliably, which attributes both to the high separation efficiency of 
the PSU and also to the high sensitivity and anti-interference ability of the developed 3D 
plasmonic device.   
 
Figure 4.14. SERS spectra a) and calibration curve b) of PSU-Chip-PLFSs with MBA as Raman 
reporter for detection of s-100 β in whole blood samples 
 
4.5 CONCLUSION  
In summary, an ultrasensitive plasmonic chip integrated test strip was developed for protein 
biomarker detection. In the presence of target protein, a 3D hierarchical architecture can be 
formed on sensing area, which forms a 3D confined plasmonic field to generating high densities 
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of hot spots, leading to a significant enhancement in SERS signal. As a result, the developed 
chip-PLFSs showed a 20-time improvement in detection sensitivity for target protein in running 
buffer compared with the results from the conventional SERS test strip. In addition, the chip-
PLFSs possessed anti-interference ability towards complex human fluids and were capable of 
sensing s-100β directly in clinical blood plasma samples and whole blood samples. The test 
results were comparable with that from the standard ELISA method, showing great promises as a 
POC tool in real applications. 
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Chapter 5: NEAR-INFRARED FLUORESCENCE IN BLOOD PLASMA 
TESTING 
5.1 CIRCULATING BIOMARKER: MIRNA-34 
Circulating microRNAs (miRNAs) are a class of cell-free miRNAs, which are stably present 
in the body fluids of many mammalian including human beings.59 Since the first description in 
the 1940s, these circulating nucleic acids were found to exhibit disease-related alternations.60 For 
example, increased levels of plasma circulating nucleic acids have been detected in a number of 
diseases even at a very early stage, such as cancers, stroke and autoimmune disease.61 
Circulating miRNAs are existing in many human fluids, such as serum, plasma, saliva, urine and 
bronchoalveolar lavage fluid, which provides diverse sensing pathways in a less-invasive mode. 
In addition, compared with detecting a low abundant of other biomarkers (e.g. proteins or tumor 
tissues), high sensitivity can be relatively feasibly achieved through detecting circulating 
miRNAs by the powerful qRT-PCR and microarray techniques. The unique features of 
circulating miRNAs, including high sensitivity, specificity and less-invasive manner expand their 
clinical importance in diseases diagnosis and monitoring.62 Up to now, around 100 circulating 
miRNAs have been identified as biomarkers which can reflect the early existence and the 
progression status of diseases.63 However, in order to detect circulating miRNAs with the current 
technologies, the extraction and purification procedures of circulating miRNAs from these 
human fluids are required. Although the demands of high specificity and sensitivity can be 
fulfilled, the complicated procedures and sophisticated instruments hindered these techniques to 
be operated only under the controlled laboratory environment. 
Fluorescence techniques have been extensively applied in biological sensing, cell screening 
and clinical diagnosis owing to their low detection of limit and ability of visualization of events 
related disease progression with short-time data acquisition.27a, 27b, 64 The performances of 
fluorescence techniques are largely dependent on the properties of the employed fluorophores. 
When choosing or designing a fluorophore, several aspects should be taken into consideration, 
including excitation and emission nature, luminescence intensity, photostability and 
biocompatibility. The use of near-infrared fluorophores (NIRF) is a promising approach for 
biomedical sensing in biological specimens. It can reduce the damage of biological samples and 
67 
 
avoid the photobleaching and background interference when visible fluorophores (VisF) are 
utilized. This is because that due to reduced absorbance and minimal scattering, the NIR 
radiation possesses high penetration ability towards tissues and biological matrices.29, 65 
Meanwhile, the NIR wavelengths falls within the biological windows with low background 
fluorescence signals, which provides elevated signal-to-noise ratio.30 These unique features offer 
great opportunity to employ NIRFs in biological fields. Nevertheless, in contrast to VisFs, the 
major shortcoming of NIRFs is limited intense. Additionally, its biocompatibility and 
photostability should also be concerned during the design of a NIRF probe.  
Dye-encapsulated silica nanoparticles appear to be an effective alternative to achieve the 
goals. The superior properties of such nanoparticles include amplified signal, outstanding 
photostability, water-solubility and viability of surface modification.31, 66 For example, the silica 
layer enables a large number of dye molecules to be encapsulated inside of one single silica 
nanoparticle, which can dramatically magnify its luminescence signal. In addition, the external 
silica layer protects the dyes from the surrounding matrix or other environment, which minimizes 
the photobleaching phenomena and increases its photostability. Moreover, silica possesses 
flexible routes for surface modifications with various types of functional groups (e.g. –NH2, -
COOH, -SH), which allows its conjugation with different biomolecules during bioassays. To 
date, many promising NIRF dye-encapsulated silica nanomaterials have been reported with 
improved stability and detection sensitivity in biological applications.67 However, the main 
challenges of current applications comprise obstacles concerning the tedious operations, lack of 
sophisticated instrument and trained personnel in less-industrialized areas or in-field 
measurements. To address this issue, many attempts have been made to develop simple and low-
cost point-of-care (POC) devices especially paper-based test strips.68 Compared to conventional 
test devices, paper test strips provide outstanding advantages including fast testing time, low cost, 
simple design and operation, which is attractive as a POC tool.12, 69 
In this study, we synthesized NIRF (cyanine 7 amine) dye encapsulated silica nanoparticles 
and integrated the nanomaterials as signal reporters into a lateral flow test strip. Compared with 
previous published methods for miRNA detection (summarized in Table 5.1), the present 
method can realize the direct detection of target miRNA in blood plasma samples without any 
sample pretreatment and complicated operation steps. It is because that the developed NIRF test 
strips take the advantages both from NIRF dyes and test strips, which avoids the issues of the 
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interference problems from visual range, meanwhile holds the promises in POC and in-field 
applications. In addition, after loading the sample solution onto the NIRF test strips, the test 
results can be read out directly with a portable fluorescent reader within 40 min. In the current 
study, circulating miRNA-34a was employed as the target molecule, owing to its potential in 
clinical applications as prognostic/predictive biomarkers in various forms of cancers, metabolic 
diseases and neurological diseases.70 Moreover, we also synthesized two VisFs encapsulated 
silica nanoparticles and compared their performances with that from the NIRF test strips. As a 
result, the NIRF test strips showed substantial improvement in detection sensitivity when target 
miRNAs were present in blood plasma specimens.  
 
Table 5.1. Comparison of the present study with previous research from publications for miRNA 
detection. 
 Methods Target miRNA LOD Linear Range  
Conventional 
Method 
Northern 
Blotting 
[1] miRNA-171 and 
miRNA-319; 
 
pM  N/A Ref 71 
 QT-PCR [2] let-7a, miRNA-16, 
miRNA-20, miRNA-21, 
miRNA-22; 
[3] miRNA-39, miRNA-54, 
miRNA-238; 
[4] hsa-miRNA-21, hsa-
miRNA-181b, hsa-miRNA-
106a 
nM-fM  N/A Ref 72 
 Microarray [5] chsa-miR-451 et al; [6] 
Let-7d et al; [7] Let-7i  
 
pM-fM N/A Ref 73 
Optical 
Method 
Colorimetric 
Method 
[8] miRNA-215; [9] 
miRNA-224; [10] 0.1 pM 
nM-fM [8] 0.075 to 10 
nM; [9] 8 pM to 
75 nM; [10] 0.20 
fM to 10 pM 
Ref 12, 
38, 74 
 Fluorescence 
Method 
[11] let-7; [12] let-7; [13] 
miRNA-21, miRNA-125b, 
pM-aM [11] 0.1 nM to 0.1 
fM & 0.1 μM to 
Ref 75 
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miRNA-96 0.1 nM; [12] 50–
200 pM [13] N/A 
 SPR [14] miR-21; [15] miRNA-
21 
pM [14] 10 pM-μM; 
[15] 5 pM to 
100 nM 
Ref 76 
Electrochemic
al Method 
Amperometric 
Method 
[16] let-7a; [17] miRNA-21; 
[18] miR-21 
fM-aM [16] 10 fM−1 
nM; [17] 0.1 pM-
1 nM [18]  10 fM 
to 10 nM 
Ref 77 
 Impedimetric [19] miRNA-34a; [20] let-
7b 
[19] 
28.1 pM 
[20] fM 
[19] 0 to ~147 
pM; [20] 2.0 fM 
and 2.0 pM 
Ref 78 
Present 
method 
Fluorescent 
Method 
MiRNA-34a 50 pM in 
50% of 
blood 
plasma 
100 nM-0.1 nM  
 
 
5.2 MATERIAL AND INSTRUMENTATIONS 
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, Na3PO4·12H2O, 
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Na3PO4·12H2O, Bovine serum 
albumin (BSA), sodium chloride, streptavidin were purchased from Sigma-Aldrich and used 
without further purification. Sucrose was purchased from VWR. 3-Triethoxylsilylpropyl succinic 
anhydride (TEPSA) was obtained from Gelest Inc. 
Silica nanosphere (60 nm) was purchased from Nanocomposix, Inc. Cyanine 7 amine 
(NIRF) was purchased from Lumiprobe, Alexa FluorTM 633 (VisF-1) was purchased from Life 
technologies, Rhodamine 6G (VisF-2) was purchased from Fluka. Blood plasma was purchased 
from US Biological Life Science (P4252-56 Plasma, Human, IgG Free). 
Target miRNAs were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and 
have the following sequences: 
Target miRNA-34a: 5’-UGG CAG UGU CUU AGC UGG UUG U -3’ 
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Detection probe (probe 1): 5’-/NH2/-AAA ACA ACC AGC-3’ 
Capture probe (probe 2): 5’-ACA CTG CCA-/Biotin/-3’ 
Control probe (secondary probe): 5’-/Biotin/-GCT GGT TGT TTT AAA/-3’ 
Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards 
(HF000MC100), and nitrocellulose membranes (HFB18004 and HFB 24004) were purchased 
from Millipore (Billerica, MA).  
E/D cPOC fluorescent readers: (365 nm/615 nm; 632 nm/650 nm; 750 nm/755 nm) were 
purchased from LRE Medical GmbH. 
5.3 PREPARATION PROCEDURES  
5.3.1 Preparation of Dye Encapsulated Silica Nanoparticles 
 
Figure 5.1. SEM images of a) commercial silica beads and b) synthesized NIRF nanoparticles. 
 
The encapsulation of dyes was accomplished by coating of commercial silica nanospheres 
with an outer layer containing fluorescent dyes. In brief, 50 μL of 100 μg/mL of fluorescent dye 
was mixed with 50 μg/mL of commercial silica nanospheres in 10 mL of ethanol solution. The 
obtained mixture was kept stirring for 20 min. Then 10 μL of TEOS and 10 uL of 28% ammonia 
hydroxide were added into the solution with 20 min intervals. All of the above reactions were 
carried out under darkness. After overnight incubation, the reaction between TEOS and ammonia 
hydroxide leads to the formation of a silica shell on the dye-nanoparticle surface. The resulting 
nanoparticles were collected by washing and re-dispersion steps through centrifuging in ethanol 
solution for several times. The final nanoparticles were re-suspended in 1 mL of ethanol solution 
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for future use. This encapsulation method guarantee the uniformity of the dye encapsulated silica 
nanoparticles and has potential to permit the synthesis of dye encapsulated silica nanoparticles 
with precisely tunable sizes through adjusting the amount of TEOS and ammonia hydroxide. 
Figure 5.1a and b show the SEM images of the commercial silica beads and the synthesized 
NIRF encapsulated silica nanoparticles respectively. From Figure 5.1b we can see that the NIRF 
nanoparticles were well dispersed and showing spherical morphology, which demonstrated that 
the silica outer layer was uniformly coated onto the silica core. Particle sizes were determined by 
Nano Measurer. The average particle sizes of the commercial silica beads and the NIRF 
nanoparticles were found to be 59.7 ± 2.0 nm and 62.5 ± 2.6 respectively. The increase in size 
reveals that the thickness of the silica outer layer was at ~ 5 nm.  
5.3.2 Labeling Detection DNA with Nanoparticles 
 
 
Peak Position 
(cm-1) 
Assignment 
2973 C-H stretch 
2927 C-H stretch 
1736 C=O stretch 
1462 C-H scissoring 
Figure 5.2, FT-IR spectra of the carboxyl-group functionalized silica nanoparticles. The peak at 
1736 cm-1 peak is assigned to the C=O stretching vibration in COOH of TEPSA. 
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The preparation of labeling DNA-NH2 with NIRF encapsulated nanoparticles followed the 
previously reported method.79 The obtained 1 mL of silica coated NIRF nanoparticles were 
mixed with 20 μL of TEPSA. The mixture solution was incubated overnight to achieve carboxyl 
group-terminated NIRF nanoparticles. The immobilization of carboxyl group onto the surface of 
silica was verified through FTIR spectra (Figure 5.2), in which the peak at 1736 cm−1 indicated 
its successful linking. After washing with ethanol and D.I. water for several times, the resulting 
nanoparticles were re-suspended in 0.5 mL of the solution containing 50 mM NHS and 200 mM 
EDC. After incubation for 2 h, the COOH group was activated. 50 μL of 20 μM ssDNA (amine 
group labeled detection DNA) solution was then added into the mixture. After overnight 
incubation, the solution was washed with a buffer solution (PBS containing 0.1% of BSA) for 
three times. The resulting nanoparticles were finally suspended in 200 μL of Eluent buffer (20 
nM of Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) and stored 
under 4 °C for future use. The schematic representation of the synthesis procedure of the NIRF 
nanoparticle is shown in Figure 5.3. The successful labeling of amine group linked detection 
DNA onto silica was examined and proved by FTIR spectra. As shown in Figure 5.4, the peaks 
at 1655 cm-1 and 1550 cm-1 were assigned to the N-H bending from the amine group linked 
detection DNA.  
 
Figure 5.3. Schematic illustrations of NIRF encapsulated silica nanoparticles synthesis and 
labeling detection DNA probe with the NIRF encapsulated silica nanoparticles.  
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Peak Position 
(cm-1) 
Assignment 
1655 N-H bend 
1550 N-H bend 
 
Figure 5.4, FT-IR spectra of the NH2 functionalized silica nanoparticles. The peak at 1655 cm-1 
and 1550 cm-1 were assigned to the N-H bending from the amine group linked detection DNA. 
 
5.3.3 Preparation of Streptavidin-Biotinylated Capture DNA Conjugates 
The preparation of streptavidin-biotinylated DNA conjugates followed the previously 
reported methods. 200 μL of 2.5 mg/ml of streptavidin was mixed with 50 mM of biotinylated 
DNA probes (capture probe/control probe). The mixture was incubated on a shaker for 1 h. After 
adding 500 μL PBS into the mixture, the solution was centrifuged in dialysis tube for 20 minutes 
at 6000 rpm under 4°C. The above steps were repeated for 3 times to remove the unbound DNA. 
The remaining solution in filter was diluted to 600 μL with PBS.  
5.3.4 Preparation of Test Strip 
The test strip consisted of four components: sample application pad, conjugate pad, 
nitrocellulose (NC) membrane, and absorption pad. All components were made from paper 
materials and they were laminated into a sheet of plastic pad orderly. The sample pad was made 
from cellulose fiber (GFCP000800) and saturated with a Tris-HCl buffer (pH 8.0) containing 
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0.23% of Triton X-100, 0.05 M of Tris-HCl and 0.15 M of NaCl. Then, the pad was dried at 
37°C for 2 h and stored in desiccators at room temperature (RT). The test line and control line on 
the NC membrane (HFB18004 and HFB 24004) were prepared by dispensing streptavidin-
biotinylated capture probe and streptavidin-biotinylated control probe solutions respectively with 
a home-made dispenser. The distance between the test and control lines was 3 mm. The 
membrane was then dried at 37°C for 1 h and stored at 4°C in a dry state. The successful 
functionalization of streptavidin-biotinylated DNA on the test line was verified through the peaks 
at 1575 cm-1 and 1542 cm-1 of FT-IR spectra in Figure 5.5, which presents the N-H bending of 
the biotin group. Finally, the sample pad, conjugate pad, NC membrane, and absorption pad were 
assembled on a plastic adhesive backing (60 mm × 30 cm) (HF000MC100). Each part 
overlapped 2 mm to ensure that the solution could migrate through the test strip during the assay. 
Test strips with a 3-mm width were cut using a paper cutter. The detection DNA probe linked 
NIRF nanoparticles were dropped on the conjugate pad prior to the test. The formation of the 
NIRF test strip was exhibited in Figure 5.6a. 
 
 
Peak Position 
(cm-1) 
Assignment 
2914 C-H stretch 
2849 C-H stretch 
1640 NO2 stretch 
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1575 N-H bend 
1542 N-H bend 
1273 NO2 stretch 
1069 C-O  stretch 
832 NO2 stretch 
 
Figure 5.5. FT-IR spectra of the capture DNA functionalized NC membrane. The peak at 1575 
cm-1 and 1542 cm-1 were assigned to the N-H bending from the biotin group linked capture DNA 
probe. 
 
 
 
Figure 5.6. Schematic illustration of a) the formation of the paper-based NIRF test strip and b) 
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miRNA-34 detection with the NIRF test strip; c) digital images of the portable fluorescent reader 
and NIRF test strip in cassette. 
5.4 ANALYTICAL CHARACTERIZATION  
5.4.1 Operation Principle 
The operation principle of the NIRF-PLFS for target circulating miRNA detection is shown 
in Figure 5.6b. The overall mechanism of the detection process involves the reaction of (a) the 
formation of NIRF linked detection DNA-miRNA complex on the conjugate pad; (b) the 
complex from step (a) was captured on to the test line via the formation of a sandwiched 
structure of NIRF/detection DNA-miRNA-capture DNA; (c) the formation of a complex of 
NIRF/detection DNA-secondary DNA on control line. The schematic illustration of the above 
mentioned steps are respectively shown in Figure 5.7. Since the presence of target miRNA 
induces the formation of a fluorescent dye linked sandwich-structured complex onto the NIRF 
test strip, consequently, the fluorescent signal is directly proportional to the quantity of target 
miRNA. During a typical assay, a NIRF test strip was firstly loaded into a cassette (Figure 5.6c), 
then 100 μL of sample solution was dropped into the sample window of the cassette. After that, 
owing to capillary force, the solution migrated along with the test strip from sample pad to 
conjugate pad, where the reaction between miRNA with detection DNA probe linked NIRF 
nanoparticles occurred. Then the resulted complexes kept moving along with the test strip until 
they reached the test line and captured by capture DNA through the formation of a sandwich 
structure (NIRF/detection DNA-miRNA-capture DNA). The rest of NIRF/detection DNA 
conjugates migrated over the test line and captured by the control line where the secondary DNA 
probe was immobilized. After reaction, the test strip was analyzed by a cPoc fluorescent strip 
reader, which is a portable handheld device (Figure 5.6c). During the data acquiring, the 
fluorescent peak intensity was used for quantitative work since the peak intensity is in proportion 
to the concentration of target miRNA. 
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Figure 5.7. Formations of complex of (NIRF/detection DNA-miRNA-capture DNA) and 
(NIRF/detection DNA-control DNA) on test line and control line respectively. 
 
5.4.2 Parameter Optimizations  
The running buffer is a critical experimental component affecting the signal readout, which 
plays a crucial role in increasing detection signal and reducing nonspecific adsorption of 
fluorescent probes on test line. In the current study, TWEEN 20 was used as surfactant in 
running buffer to control the flow rate and reduce the background fluorescent signal. As shown 
in Figure 5.8a, with the increasing amount of TWEEN 20, the fluorescent S/N ratio rises 
gradually and then tends to a constant value at 0.3%, which is chosen as the optimized TWEEN 
20 amount. The reaction time is another important parameter of the NIRF test strip, which 
improves the bounding stability of detection reagent and target miRNA with the capture DNA 
immobilized test line. Meanwhile, increasing reaction time can help reduce background signal as 
the nonspecific adsorbed fluorescent probe on test line can be washed away by the running 
buffer. The reaction time was optimized from 1 to 50 min, and as shown in Figure 5.8b, the 
optimal S/N is obtained from the reaction at 40 min.  
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Figure 5.8. Experiment optimizations with NIRF test strips for miRNA measurements. a) Effect 
of surfactant of TWEEN 20 amount in running buffer; B) effect of the reaction time; C) effect of 
the volume of NIRF/detection DNA conjugate; D) effect of the dispensing times of the capture 
DNA on test line on the S/N ratio of the NIRF based test strip. 
 
The amounts of detection DNA-NIRF conjugate and capture DNA on test line can 
substantially affect the signal intensity. From Figure 5.8c we can see that with the conjugate 
volume increase, the S/N ratio increases because more NIRF nanoparticles are captured by test 
line in the present of miRNA. When the volume of conjugate exceeds 7 μL, the S/N ratio 
decreases owing to that the increased non-specific adsorption of NIRF nanoparticles on test line. 
Therefore, 7 μL of NIRF conjugate is optimal. The capturing capacity of NIRF nanoparticles 
onto test line is depended on the capturing reagent amount. In the current study, 3 times of 
dispensing of capturing reagent onto test line was found to be the optimal and used in the 
following experiment (Figure 5.8d). 
5.4.3 Stability Comparison 
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Figure 5.9. Stability comparison of different dyes: a) Cy7, b) Alexa 633 and c) Rhodamine 6G  
encapsulated silica nanoparticles in buffer, 50% of plasma and 100% of plasma.  
 
In order to demonstrate the advantages of NIRF in increasing the photostability and anti-
interference capacity, the effect of biological matrices on the fluorescent intensity of the NIRF 
and VisF dyes encapsulated silica nanoparticles was investigated. The results are exhibited in 
Figure 5.9. The X axis of the figures presents the position of the nanoparticles on the test strip. 
Figure 5.9a, b and c respectively describes the fluorescent spectra of NIRF (Cy7), VisF-1 
(Alexa 633) and VisF-2 (Rhodamine 6G) encapsulated silica nanoparticles in the present of 
buffer (green line with squares), 50% of blood plasma (orange line with spheres) and 100% of 
blood plasma (pink line with triangles). The corresponding excitation/emission spectra of the 
employed dyes are shown in Figure 5.10.  
 
 
 
Figure 5.10. Excitation and emission spectra of the a) cyanine; b) Alexa 633 and c) Rhodamine 
6G respectively. The information source of the spectra is from Lumiprobe, Life technologies and 
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Fluka respectively.  
From Figure 5.9a we can see that there is no manifest change in the fluorescent intensity 
when NIRF nanoparticles were suspended even in 100% of blood plasma specimen in 
comparison to that in running buffer. This is because that the wavelengths of the NIRF 
nanoparticles fall within the biological window, which provides increased transparency toward 
biological matrices. As a result, in that optical region, there is less absorbance, minimal 
scattering and reduced background fluorescent interference, which endowing the NIRF 
nanoparticles with favorable stability in biological matrices and, accordingly, offering accurate 
measurement for bioanalysis. In contrast to the NIRF nanoparticles, the VisF-1 encapsulated 
silica nanoparticles showed fluorescent intensity decreases by 23.6% and 37.8% (Figure 5.9b) 
respectively in 50% and 100% of blood plasma. The results implied that there was great 
scattering interference from biological matrix, which severely influence its luminance intensity. 
In the case of VisF-2, the situation was even worse. Substantial signal decreases were observed 
from the VisF-2 nanoparticles when they existed in the biological matrices (Figure 5.9c). 
Moreover, the baselines of the fluorescent spectra were wavy and oscillating, which were 
contributed to the background interference from test strip materials and surrounding environment, 
leading to imprecise signal response and low detection sensitivity. Interestingly, compared with 
VisF-2 nanoparticles (Figure 5.9c), VisF-1 nanoparticles (Figure 5.9b) possessed smooth and 
flat spectrum baselines, indicating that the background interference played less effect on the 
VisF-2 nanoparticles. This is because that the wavelengths of VisF-2 nanoparticles fall near the 
left border of the NIR region, which endowed the nanoparticles with improved anti-interference 
capacity towards the biological matrices and surrounding environment. The above findings 
revealed that the NIRF played a vital role in elevating the photostability and avoiding the 
background interference from surrounding environment, holding promises in direct bioanalysis.  
5.4.4 Analytical Characterization  
In order to evaluate the performances of the NIRF-PLFSs, sample solutions containing 
different concentrations of miRNA-34 (ranging from 0 to 100 nM) were measured under the 
optimal experimental conditions. As descripted in Figure 5.11a, the fluorescent response ((I-
I0)/I0) linearly increases with the increasing of logarithm of target circulating miRNA 
concentration, and the corresponding regression equation was y = 7.2x + 18.6 with a correlation 
coefficient of 0.93. The detection limit of the NIRF-PLFS for target circulating miRNA-34 was 
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found to be 20 pM, which was estimated based on three times of signal-to-noise ratio. A linear 
detection range from 50 pM to 100 nM was obtained and was suitable for quantitative work. The 
above results implied that the developed NIRF-PLFS were working properly and reliably. The 
fluorescent signal stability was determined through measuring NIRF-PLFS with three 
concentration levels of miRNA-34 (50 nM, 1 nM and 0 nM). Each measurement of miRNA was 
repeated six times on six NIRF-PLFS. Results for the three concentration levels of miRNA 
yielded a RSD respectively of 9.0%, 3.4% and 2.7%. The results exhibited outstanding 
reproducibility, which clearly verified that the silica layer ameliorated the stability of the NIRF 
encapsulated nanoparticles, thereby allowing reproducible fluorescent responses to be obtained 
from different test strips constructed under the same condition. 
In order to validate the anti-interference performance of the NIRF-PLFS in the present of 
complex biological samples, various concentrations of miRNA was spiked with 50% of blood 
plasma solutions. Then the resulted mixtures were examined by the NIRF-PLFSs. The test 
results were described in Figure 5.11b. Compared with the data from Figure 5.11a, under the 
same concentration of miRNA, there were no substantial signal decreases observed when the 
measurements were carried out in 50% of blood plasma, which indicated that the complex 
sample matrix exhibited very slight effect on the NIRF detection. As a result, a LOD of 50 pM of 
miRNA was achieved when the NIRF-PLFSs were operated in 50% of blood plasma. A 
calibration curve was obtained by plotting the response versus logarithm of miRNA 
concentration, which was ranged from 0.1 nM to 100 nM. 
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Figure 5.11. MiRNA-34 detection with various concentrations in buffer with a) NIRF, c) VisF-1 
and e) VisF-2 nanoparticles incorporated test strips; and in 50% of plasma with b) NIRF, d) VisF-
1 and f) VisF-2 nanoparticles incorporated test strips. (I presents the fluorescent intensity in the 
present of various concentrations of miRNA-34; while I0 presents the fluorescent intensity in the 
absent of miRNA-34). 
 
5.4.5 Performance Comparison 
 
  NIRF test strip 
(Cy7) 
VisF-1 test strip 
(Alexa 633) 
VisF-2 test strip 
(Rhodamine 6G) 
Buffer Linear 
Range 
100 nM-50 pM 100 nM-50 pM 100 nM-0.1 nM 
LOD 20 pM 5 pM 50 pM 
50% 
Plasma 
Linear 
Range 
100 nM-0.1 nM 100 nM-0.5 nM 100 nM-10 nM 
LOD 50 pM 100 pM 5000 pM 
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Table 5.2. Comparisons of test results from VisF and NIRF test strips for miRNA detection in 
buffer and in 50% of blood plasma samples.  
 
To further verify the advanced anti-interference capacity of NIR nanoparticles, the 
comparisons among the VisF-1, VisF-2 and the NIRF incorporated PLFSs were conducted 
through detecting target miRNA in 50% of blood plasma specimens. In order to facilitate the 
comparison, all of the synthesis procedures and tests conditions of the NIRF and the VisFs test 
strips were kept same. The obtained calibration curves and the corresponding data including 
LODs and linear ranges were presented and summarized respectively in Figure 5.11 and Table 
5.2. From the data we can see that in running buffer, the LODs for target miRNA from the VisF-
2 and NIRF-PLFSs were at the same concentration level. But when the measurements were 
carried out in 50% of blood plasma, the LOD from NIRF-PLFS was 100 times lower than that 
from the VIF-2-PLFSs (5000 pM vs 50 pM). In addition, in comparison to the fluorescent 
responses from VisF-2-PLFSs for measuring 10 nM of miRNA in running buffer, a five-time 
decrease of fluorescent response was observed when the tests were conducted in 50% of blood 
plasma samples (Figure 5.11b and f). The severe signal drops are attributed to substantial 
scattering loss of the excitation and emission light in the biological matrix. In contrast, the 
fluorescent responses from the NIRF-PLFSs were found to be very stable even for low 
concentration detection of target miRNA in 50% of blood plasma samples. Moreover, the slope 
of the calibration curve from the NIRF-PLFSs was comparable to that from the running buffer, 
which demonstrated that the detection sensitivity of the NIRF-PLFS wasn’t affected significantly 
when the system was operated in biological samples. Consequently, the LOD for miRNA on the 
NIRF-PLFS was found to be 50 pM, which was at the same concentration level compared to that 
from the running buffer. 
5.5 CONCLUSION  
In this work, we developed a strategy for the synthesis of novel NIRF dye encapsulated 
silica nanoparticles through coating of commercial silica beads with NIRF dyes and a silica outer 
layer. The silica coating layer enables numerous NIRF to be encapsulated into the nanoparticle, 
leading to substantial fluorescent enhancement. Additionally, the silica layer can protect the dyes 
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from the complex biological matrix. Moreover, the NIRF nanoparticles present advantages over 
VisF nanomaterials in terms of improved anti-interference ability and minimized background 
interference signal. As a result, the NIRF-PLFSs showed a two-order of magnitude improvement 
in detection sensitivity for miRNA in 50% of blood plasma samples, which is expected to hold 
promise as a POC tool in biological assays and other bio-applications.  
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Chapter 6: AMPLIFICATION STRATEGY MODIFIED TEST STRIP IN 
PLASMA TESTING 
6.1 NUCLEASE-ASSISTED AMPLIFICATION TECHNIQUE  
MicroRNAs (miRNAs) are a class of single-stranded non-coding RNA, which regulate gene 
expression by either inhibition of translation or mRNA degradation.80 Studies have shown that 
alterations in miRNA-expression play a significant effect on biological processes of disease 
development and progression, including proliferation, differentiation and apoptosis.81 Thus, 
miRNAs have become clinical promising biomarkers and have been explored in a variety of 
studies. Accurate and sensitive measurement of miRNAs holds great significance for detecting 
and predicting the resistance of different types of malignancies as well as for monitoring 
treatment response.82 However, the major challenge of miRNA measurement is that the low 
abundance of microRNAs but the high sequence homology within miRNA families in tissues, 
cells and circulating system. Hence the standard approaches for miRNA measurements, 
including Northern blotting and microarray are hindered by their intrinsic low sensitivity and 
specificity limitations. The quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) is a well-established gold standard method for miRNA measurements, which exhibits 
dramatically improvement in detection sensitivity, leading to single molecule assay.83 However, 
the short length of miRNAs requires the design of short primers and precise control of 
temperature cycling for successful amplification, which decreases the efficiency of PCR and 
increases the chances of nonspecific amplification. Moreover, the approaches depend on 
laboratory-oriented sophisticated instruments, expert personnel and tedious operations, which 
severely hamper their practical application, especially in remote and resource-limited and areas.  
Recently, a variety of novel amplification strategies have been developed to improve the 
detection sensitivity and adaptability for miRNA detection, including nanomaterial-based 
miRNA detection84 and various kinds of nucleic acid amplification techniques75c, 85, including 
rolling circle amplification (RCA),86 exponential isothermal amplification (EXPAR)87 and 
nuclease-assisted amplifications (NAA).88 Nanomaterial-based amplification mainly depends on 
the unique properties of nanomaterials, such as inherent high carrier capacity, and outstanding 
conductivity and catalytic ability, offering the platform with eminent optical and electrochemical 
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features.89 While NAA techniques primarily rely on an enzymatic process, which generates 
thousands to millions of copies of a specific DNA segment. For instance, the RCA technique 
enables the amplifications of a short DNA or RNA primer in the present of a circularized padlock 
probe and the corresponding special DNA or RNA polymerases. RCA is a powerful tool to detect 
DNA mutation, owing to the fact that even a single mismatch in the ligation junction does not 
allow circularizing of the probe (Rolling circle amplification: a versatile tool for chemical 
biology, materials science and medicine.90 In the case of EXPAR technique, one simple template 
and two enzymes are required. The two enzymes are respectively utilized in nicking 
endonuclease reaction and polymerase strand extension. EXPAR technique has gained increase 
attention in amplifying of low-abundance miRNA due to its high sensitivity and good tolerance 
to the inhibitory components in the clinical samples.91 
Although the above mentioned techniques offer some advantages in miRNA amplification, 
they have practical limitations in time, cost, and simplicity. Among the NAA techniques, the 
duplex-specific nuclease (DSN) assisted signal amplification offers a rapid, convenient but 
powerful alternative strategy for highly sensitive miRNA detection. It enables the linear signal 
amplification without changing the quantity of the target miRNA.92 In addition, the DSN-
mediated signal amplification strategy owns unique advantages of high amplification efficiency, 
isothermal nature, and no nonspecific priming. The mechanism of DSN assisted amplification 
strategies are based on the cleavage of the single strand DNA probe only when it is in a DNA-
RNA hybrid, while keeping the RNA intact. Then the target RNA acts as a template for a fresh 
DNA probe and repeats the process of hybridization and cleavage, leading to signal 
amplification.93 Various transducers have been integrated into DSN based sensors for achieving 
ultra-sensitivity for miRNA measurements, including colorimetry,93c, 94 fluorescence88b, 95 and 
electrochemistry.96 Although the procedures have been simplified compared with other NAA 
techniques, most of the reported DSN based sensors still suffer from complicated nanofabrication 
and multiple step operations, which cannot meet the demands of point-of-care (POC) 
applications.  
Paper-based lateral flow strips (PLFSs) are one of the best well-known POC tools, which 
possess the advantages of user friendly operation, portability and low cost. PLFSs have been 
employed in a variety of fields, such as environmental monitoring, food safety, and clinical 
diagnosis for detecting various biomolecules and chemical contaminants. However, PLFSs 
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rarely involves in detection of early-stage diseases, owing to the fact that the sensitivity and 
accuracy of a PLFT are always sacrificed in order to simplify test procedures and accelerating 
sample screening. In the current study, in order to realize high sensitivity measurement of 
miRNA, the DSN assisted signal amplification strategy was introduced to modify PLFSs. The 
developed DNS-PLFSs can sustain the properties of a POC tool, at the same time, realizing 
ultrasensitive measurement of miRNA. In addition, near-infrared fluorescent NIRF (dylight 755) 
encapsulated silica nanoparticles were employed as signal reporters, which can further amplify 
signal response, meanwhile reduce the interference signal of the non-specific biomolecules from 
human fluids. As a result, the proposed device allowed a quantitative evaluation of miRNA-34a 
with a detection limit (LOD) of 0.1 pM in running buffers and a LOD of 0.5 pM in blood plasma 
samples. The obtained LOD of miRNA-34a is below the cut-off value of that in the plasma 
samples of stroke patients, exhibiting great potential as a POC miRNA quantification tool for use 
in biomedical research and clinical diagnosis. Moreover, compared with other miRNA 
amplification methods, the developed DSN-PLFS shows advantages in terms of simplicity, low 
cost, fast response (within 40 min) and user-friendly properties. 
6.2 MATERIALS AND METHODS  
6.2.1 Reagents and Materials 
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, Na3PO4·12H2O, 
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Bovine serum albumin (BSA), 
sodium chloride, streptavidin were purchased from Sigma-Aldrich and used without further 
purification. Sucrose was purchased from VWR. 3-Triethoxylsilylpropyl succinic anhydride 
(TEPSA) was obtained from Gelest Inc. Silica nanosphere (60 nm) was purchased from 
Nanocomposix, Inc. DyLight™ 755 NHS Ester was purchased from Thermo Scientific. Blood 
plasma was purchased from US Biological Life Science (P4252-56 Plasma, Human, IgG Free). 
Duplex-specific nuclease (DSN) kit (containing DSN enzyme, DSN storage buffer, 10X DSN 
master buffer, 2X DSN stop solution and control template) was purchased from Evrogen. RNase 
inhibitor was purchased from Sigma-Aldrich. Water glass distilled PCR Certified was purchased 
from VWR. 
Target miRNAs, detection probes and capture probes were purchased from Integrated DNA 
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Technologies, Inc. (Coralville, IA) and have the following sequences: 
Target miRNA-34a:  
5’-UGG CAG UGU CUU AGC UGG UUG U -3’ 
miRNA sequence with two mismatches: 
5’-UGU CUG UGU CUU AGC UGG UUG U -3’ 
Detection probe:  
5’-/AmMC6/-GCG CGC GCA CAA CCA GCT AAG ACA CTG CCA-/Bio/-3’ 
Capture probe:  
5’-/Biotin/GCG CGC GC-3’ 
Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards 
(HF000MC100), and nitrocellulose membranes (HFB18004 and HFB 24004) were purchased 
from Millipore (Billerica, MA). E/D cPOC fluorescent readers (750 nm/755 nm) was purchased 
from LRE Medical GmbH. 
6.2.2 Instruments and Characterization  
Fourier transform infrared (FT-IR) spectra were obtained with Thermo Nicolet 6700 
spectrometer. A scanning electron microscope (JEOL-JSM-7600F) was used to image the 
fluorescent dye encapsulated nanoparticles. 
 
Figure 6.1. SEM images of a) commercial silica beads and b) synthesized NIRF nanoparticles. 
 
6.2.3 Synthesis of Nanoparticles 
The encapsulation of dyes was accomplished by coating of commercial silica nanospheres 
with an outer layer containing fluorescent dyes. In brief, 50 μL of 100 μg/mL of fluorescent dye 
was mixed with 50 μg/mL of commercial silica nanospheres in 10 mL of ethanol solution. The 
obtained mixture was kept stirring for 20 min. Then 10 μL of TEOS and 10 uL of 28% ammonia 
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hydroxide were added into the solution with 20 min intervals. All of the above reactions were 
carried out under darkness. After overnight incubation, the reaction between TEOS and ammonia 
hydroxide leads to the formation of a silica shell on the dye-nanoparticle surface. The resulting 
nanoparticles were collected by washing and re-dispersion steps through centrifuging in ethanol 
solution for several times. The final nanoparticles were re-suspended in 1 mL of ethanol solution 
for future use. This encapsulation method guarantee the uniformity of the dye encapsulated silica 
nanoparticles and has potential to permit the synthesis of dye encapsulated silica nanoparticles 
with precisely tunable sizes through adjusting the amount of TEOS and ammonia hydroxide. 
Particle sizes were determined by Nano Measurer. Figure 6.1a and b show the SEM images of 
the commercial silica beads and the synthesized NIRF encapsulated silica nanoparticles 
respectively. The average particle sizes of the commercial silica beads and the NIRF 
nanoparticles were found to be 59.6 ± 2.2 nm and 64.5 ± 3.3 respectively. The increase in size 
reveals that the thickness of the silica outer layer was at ~ 5 nm. The fluorescence emission 
spectrum of the synthesized NIRF nanoparticles is presented in Figure 6.2. The wavelength of 
the maximum fluorescence emission is at 769 nm.   
 
Figure 6.2. Fluorescence emission spectrum of the synthesized NIRF nanoparticles. 
6.2.4 Labeling detection DNA with Nanoparticles 
The preparation detection DNA labeled with NIRF NPs followed the previously reported 
method. The obtained 1 mL of NIRF NPs was mixed with 20 μL of TEPSA. The mixture 
solution was incubated overnight to achieve carboxyl group-terminated NIRF NPs. The 
successful conjugation of carboxyl-group onto the surface of NIRF NPs was confirmed by FT-IR 
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spectra (Figure 6.3). After washing with ethanol and D.I. water for several times, the resulting 
nanoparticles were re-suspended in 0.5 mL of the solution containing 50 mM NHS and 200 mM 
EDC. After incubation for 2 h, the COOH group was activated. 50 μL of 20 μM of DNA (amine 
group labeled detection DNA) solution was then added into the mixture. After overnight 
incubation, the solution was washed with a buffer solution (PBS containing 0.1% of BSA) for 
three times. The resulting nanoparticles were finally suspended in 200 μL of Eluent buffer (20 
nM of Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) and stored under 
4 °C for future use. The successful conjugation of the detection DNA probe onto the NIRF NPs 
was confirmed by the FT-IR spectra (Figure 6.4). 
 
Figure 6.3. FT-IR spectra of the carboxyl-group labeled NIRF NPs. The peak at 1709 cm-1 peak 
is assigned to the C=O stretching vibration in COOH of TEPSA. 
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Figure 6.4. FT-IR spectra of the detection DNA probe functionalized NIRF NPs. The peaks at 
1655 and 1541 cm-1: correspond to the N-H bending in the NH2 labeled DNA. 
6.2.5. Labeling Biotinylated Detection DNA with Streptavidin 
The biotin-lated detection DNA probe (50 mM) /NIRF NPs was mixed with 200 μL of 2.5 
mg/ml of streptavidin. The mixture was incubated on a shaker for 1 h. The solution was 
dispensed on the sample pad of the PLFS.  
6.2.6 Preparation of Test Strip 
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Figure 6.5. Schematic illustration of the DSN-PLFS.  
 
Figure 6.5 exhibits the schematic illustration of the fabricated DSN-PLFS, which consists of 
five components: a sample pad (reaction chamber), a thermoelectric controller, NC membrane, a 
paper bridge and an absorption (wick) pad. All the components were mounted on a common 
backing layer (typically an inert plastic, e.g., polyester). The sample pad was saturated with a 
Tris-HCl buffer (pH 8.0) containing 0.23% Triton X-100 and 0.05 and 0.15 M NaCl. The pad 
was then dried at 37 °C for 2 h and stored in a desiccator at room temperature (RT). Then, 5 μL 
of NIRF NPs labeled detection DNA probe was dispensed on the samples pad of the PLFS. After 
the sample pad was dried at 37 °C for 10 min, 0.25 U of DSN was loaded onto it and then the 
sample pad was dried and stored at 4 °C under a dry condition. 0.5 μL of 1 mg/mL capture 
antibodies was dropped onto the NC membrane to form a test dot. The membrane was then dried 
and stored at 4 °C under a dry condition. Finally, the sample pad, NC membrane and the 
absorption pad were successively assembled onto a plastic adhesive backing layer. The NC 
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membrane and absorption pad were overlapped with 2 mm to ensure that the solution was able to 
flow across the components. Each strip was cut to be 3 mm wide by a paper cutter (Swingline 12 
in. ClassicCut Lite Trimmer). During the test, the PLFS was soaked into a tube containing 100 
μL of sample solution with concentration of target miRNA. Then the tube was incubated in an 
oven under 60 °C for 20 min. After reaction, a paper bridge (8 mm × 3 mm) was placed in the 
gap between the sample pad the NC membrane, enabling the flow of the sample solution to 
migrate to the detection area on the NC membrane. After 20 min reaction, the PLFS was 
analyzed by a portable fluorescent reader. The fluorescent peak intensity was in proportion to the 
concentration of target antigen, which was used for quantitative work 
 
 
Figure 6.6. Schematic illustration of the signal amplification principle of the DSN-LFTS. 
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6.3 RESULTS AND DISCUSSION  
6.3.1 Operation Principle  
The procedure of signal amplification of a DSN-PLFS is illustrated in Figure 6.6. As shown 
in the figure, single strand detection DNA probes labeled NIRF NPs are functionalized on the 
sample pad. The sequence of the detection DNA probe is specifically designed based on the 
sequences of the target miRNA and the capture DNA probe. The part II of the detection probe is 
fully complementary with target miRNA; while the part I is complementary with capture DNA 
probe on the test area. Upon the addition of target miRNA, it is hybridized with the part II of the 
detection probe, leading to the formation of miRNA-detection DNA/NIRF NPs heteroduplex on 
the sample pad. Owing to the present of DSN, the part II DNA probe in the heteroduplex is 
immediately degrades, at the same time, the target miRNA and the remained part I DNA probe 
linked NIRF NPs are released. Following the specific cleavage reaction, the released miRNA 
subsequently hybridizes with the part II probe of the remaining detection DNA to repeat the 
hybridization/cleavage cycle, leading to the concentration amplification of the NIRF NPs linked 
DNA probes. The detailed illustration of this amplification procedure is presented in Figure 6.7.  
 
Figure 6.6. Detailed illustration of the signal amplification principle of the DSN-LFTS. 
 
After the amplification reaction, a paper bridge is placed between the sample pad and the NC 
membrane to guide the liquid migration from the amplification chamber to the NC membrane, 
where the capture DNA probe is functionalized. When the solution migrates to the test line, the 
functionalized capture DNA on the test line can grab the complex of part I DNA probe-NIRF NP 
through DNA complementary hybridization. At this moment, the NIRF NPs are accumulated on 
95 
 
the test line and the captured amount is in proportion to the concentration of the target miRNA, 
which can be employed for quantification work. In the absent of target miRNA, detection DNA 
linked NIRF NPs cannot be released owing to the fact that DSN is only active towards with the 
DNA inside of the DNA/RNA heteroduplex but inactive towards single-stranded DNA and RNA. 
The PLFS is then analyzed by a portable handheld fluorescent strip reader, which has been 
exhibited in Figure 5.6c. 
 
6.3.2 Optimizations 
 
Figure 6.8. Optimization of the experiment conditions for DSN-PLFS. a) Effect of the DSN 
amount on the fluorescent signals of the PLFSs, b) effect of the NIRF NPs/detection DNA probe  
on the S/N ratio, c) effect of the volume of capture DNA probe on the S/N ratio. 
     In order to optimize the sensor performance, the DSN-PLFS was employed to measure 10 pM 
of miRNA. Since the DSN significantly influences the hybridization/cleavage reactions and the 
released amount of NIRF NPs, therefore, the amount of DNS in this amplification system was 
studied. As shown in Figure 6.8a, the signal intensity of the fluorescent peak increases with the 
growing amount of DSN until it reaches 0.25 U. Further increase in the DSN amount shows little 
effect on the increase of the peak intensity. Therefore, the optimal amount of DNS was 0.25 U. 
The amount of the detection DNA-NIRF NPs and the concentration of capture DNA probe on 
the test line are another two important parameters, because both of them affect the ability of 
DSN-PLFS to capture the NIRF NPs on the test line, which significantly affects the signal 
intensity and detection sensitivity. As shown in Figure 6.8b, c, the optimal amount of the 
detection DNA-NIRF NPs was 5 μL, and 5 μL of the capture DNA probe was the best.  
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Figure 6.9. Optimization of the experiment conditions for DSN-PLFS. a) Effect of the on the 
reaction temperature of the DSN-PLFSs, b) effect of the reaction time on the S/N ratio of the 
DSN-PLFSs. 
The optimal temperature of DSN-PLFS was determined tuning reaction temperature varying 
from 25 ºC to 70 ºC. Under the conditions employed, the highest S/N ratio was observed at 55 °C. 
Further increases in temperature were accompanied by a signal decrease (Figure 6.9a). This 
might reflect enzyme denaturation. We also evaluated the effect of incubation time of enzyme 
amplification reaction on S/N ratio (Figure 6.9b). We found that increases in incubation time 
were accompanied by increases in S/N ratio until incubation time reached 25 min. After 25 min, 
S/N ratios were remained constant. Therefore, the optimal incubation time of the enzyme 
amplification reaction was 25 min  
6.3.3 Performance in Running Buffer  
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Figure 6.10. Peak intensity of the fluorescent signal obtained from the DSN-PLFS in running 
buffer with different concentrations of miRNA (ranging from 0 to 100 nM). 
In order to further evaluate the performances of the DSN-PLFS, sample solutions containing 
different concentrations of miRNA-34 (ranging from 0 to 100 nM) were measured under optimal 
experimental conditions. During a typical test, a DSN-PLFS was soaked into a tube which 
contains 100 μL of sample solution. After the amplification reaction in the oven for 20 min and 
the reaction of the capturing NIRF NPS on the test line for another 20 min, the fluorescent 
response of the DSN-PLFS was recorded. As descripted in Figure 6.10, the fluorescent intensity 
increases with the increasing of miRNA concentration, which indicates that the DSN-PLFS is 
working properly. The calibration curve showed a linear range from 175 fM to 100 nM. The 
detection limit of the DSN-PLFS for target miRNA was found to be 150 fM, which was 
estimated based on three times of signal-to-noise ratio. Compared with the sensitivity of NIRF-
PLFS in Chapter 5, an improvement in sensitivity of three-orders of magnetite was obtained by 
the developed DSN-PLFS for miRNA measurement in running buffer samples.  
6.3.4 Performance in 50% of Blood Plasma 
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Figure 6.11. The fluorescent intensities of the DSN-PLFS test zones in the presence of 500 fM 
of miRNA-34, 500 fM of interference miRNA and 0 fM of miRNA in running buffer and 50% of 
plasma. 
Anti-interference ability is an important parameter to evaluate a biosensor. Before the test 
was conducted in real plasma samples, selectivity test was carried out by employing miRNA 
molecule with two mismatches of bases towards target miRNA-34.  As demonstrated in Figure 
6.11, compared with the target signals, signals from the interference tests are comparable with 
the signals generated from control experiments and can be negligible, indicating that the 
developed DSN-PLFS exhibits  good selectivity towards interference miRNA molecules. The 
intrinsic advantages can merit miRNA detection in complex real samples. 
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Figure 6.12. Peak intensity of the fluorescent signal obtained from the DSN-PLFS in 50% of 
blood plasma with different concentrations of miRNA (ranging from 0 to 100 nM). 
The performance of the DSN-PLFS was then studied in the complex human fluids. 50% of 
plasma sample solutions containing different concentrations of miRNA-34 (ranging from 0 to 
100 nM) were measured under optimal experimental conditions. After the reactions, the 
fluorescent response of the DSN-PLFS was recorded by a portable fluorescent reader. As 
descripted in Figure 6.12, the fluorescent intensity increases with the increasing of miRNA 
concentration. The fluoresce cent peak intensity (y) versus the miRNA-34 concentration (x) was 
fitted as y = 311.2x + 1198.4 with the relative coefficient (R2) of 0.95, showing a linear detection 
range from 500 fM to 100 nM, achieving a LOD of 300 fM. The LOD was estimated according 
to three times of signal-to-noise ratio. Compared with the sensitivity of NIRF-PLFS in Chapter 
5, an improvement in sensitivity of two orders of magnitude was obtained by the developed 
DSN-PLFS for miRNA measurement in running buffer samples. Our experimental results show 
the DSN-PLFS developed in the present work can work for miRNA-34 detection in blood 
plasma. 
6.3.5 Measurement of miRNA-34 Biomarker in Clinical Blood Plasma Samples 
The calibrated DSN-PLFS was employed to measure the miRNA-34 biomarker level in 
clinical blood plasma taken from stroke patients. Figure 6.13 shows the miRNA-34 
concentrations in six clinical blood plasma samples measured by the DSN-PLFS. The results 
indicated that the developed DSN-PLFS can work properly in clinical patient samples and can 
meet the demands for measuring trace amount of miRNA biomarkers directly from clinical 
samples. Compared with clinical standard PCR approach, the developed DSN-PLFS exhibits 
advantages in simplicity, shorter reaction time, low cost and used friendly. 
100 
 
 
Figure 6.13. miRNA-34 concentrations in clinical blood plasma samples, which were measured 
by DSN-PLFS. 
6.4 CONCLUSION 
The DSN-PLFS was developed for ultrasensitive measurement of stroke biomarker 
microRNA-34 in blood plasma samples. DSN assisted amplification technique was employed to 
modify the PLFS for improving the sensor performance. After signal amplification, the DSN-
PLFS can amplify fluorescent response, leading to an improvement in detection sensitivity with 
two-orders of magnitude. The obtained LOD was below the cut-off value that presents in the 
blood samples of stroke patients. Moreover, the DSN-PLFS shows advantages over the standard 
PCR approach, including low cost, portability, short operation time, and simple operation 
procedure. These merits endow the DSN-PLFS with great potential to be employed as a POC 
tool for monitoring the miRNA biomarkers in biological samples. The DSN-PLFS was 
successfully employed for detection of miRNA-34a in clinical blood plasma samples. Obviously, 
the DSN-PLFS has advantages over the standard PCR approach, including low cost, portability 
and short operation time. These merits endow the DSN-PLFS with great potential to be 
employed as a POC tool for monitoring the miRNA biomarkers in real-world samples. 
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Chapter 7 CONCLUSION AND OUTLOOK 
 
This dissertation summarized the background, recent advances and obstacles of PLFS devices 
for disease biomarker detections. In order to solve the problems and fill the gaps between the 
PLFSs and the practical POC devices, several strategies have been proposed: 
1) Two parallel routes of ultrasensitive techniques: SERS and NIR fluorescence techniques 
have been employed in PLFSs to build proof-of-concept sensors and improve detection 
sensitivity; 
2) Synthesized SERS and NIRF nanomaterials with silica coating layers to protect the 
nanomaterials from the interference from the surrounding environment, leading to the 
improvement in anti-interference capacity; 
3) Tuned the SERS and NIRF nanomaterials to the near-infrared window to reduce the 
interference signals from surrounding environment and biological matrices; 
4) Fabricated blood plasma separation unit (PSU) to reduce the interference from the RBCs 
from whole blood samples; 
5) Integrated SERS-PLFS with plasmonic chip to form 3D confined plamonic field for further 
improving signal intensity and sensitivity; 
6) Modified PLFSs with duplex specific nuclease (DSN)-mediated signal amplification 
strategy for improving detection sensitivity.  
As a result, the developed PLFSs in this dissertation can realize accurate and direct 
measurement of biomarkers from clinical samples, showing great advantages as a practical POC 
device. Despite the progress that has been achieved in this dissertation, there still exist some 
issues to be solved. (i) Although the proposed PLFS has realized disease biomarker detection 
from clinical samples, it is still difficult to employ PLFS to indicate a specific disease if only one 
biomarker is detected during one trial. Therefore, a high-throughput PLFS which enables 
multiple biomarker measurements can substantially improve the diagnostic specificity. (ii) 
Compared with paper materials, the employed blood plasma filtration membrane in this 
dissertation is relatively more expensive. In order to further decrease the cost of the device, other 
less-expensive materials, such as porous polymers or general filter paper might provide 
alternative choices for filtrating plasma from whole blood samples. (iii) During one PLFS test, at 
least 100 μL of aqueous solutions or clinical samples is required, which is not applicable for the 
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applications of miniscule amounts of samples and reagents. The future innovative research is 
expected to introduce microfluidic technique with PLFS through fabricating microfluidic 
channels on PLFS surfaces through wax-printing technique to solve this problem.  
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